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resumo 
 
 
O elevado número de gravidezes indesejadas a nível mundial e o facto de os 
contracetivos masculinos estarem limitados ao preservativo e à vasectomia 
refletem a necessidade urgente de desenvolvimento de novos métodos 
contracetivos. O mecanismo de aquisição de mobilidade dos espermatozoides 
no epidídimo constitui um alvo perfeito para novos agentes contracetivos dado 
que apenas a maturação pós-testicular é afetada. Sabe-se que a proteína 
fosfatase 1 subunidade gama 2 (PPP1CC2), uma isoforma presente apenas 
nos testículos e espermatozoides, é essencial para a aquisição de mobilidade 
no epidídimo. As interações proteína-proteína (PPIs) têm surgido como uma 
promissora classe de alvos terapêuticos e os cell-penetrating peptides (CPPs) 
representam um reconhecido sistema de entrega intracelular de sequências 
peptídicas com o potencial de modular PPIs. Assim, o principal objetivo deste 
trabalho é modular complexos PPP1CC2 específicos de testículo e 
espermatozoide e, consequentemente, a mobilidade dos espermatozoides 
recorrendo a sequências peptídicas covalentemente ligadas a CPPs. Os 
resultados mostram que ambos os péptidos testados são capazes de modular 
a mobilidade dos espermatozoides, mesmo com curtos períodos de incubação, 
aumentando o número de espermatozoides imóveis. Adicionalmente, foi 
demonstrado que o péptido que mimetiza a interface de interação entre 
PPP1CC2 e uma a A-kinase anchor protein (AKAP4) – um interactor específico 
no espermatozoide – interfere com a interação PPP1CC2-AKAP4, resultando 
em espermatozoides imóveis. O péptido que mimetiza os 22 aminoácidos do 
C-terminal da PPP1CC2 atua disrompendo a interação entre a PPP1CC2 e 
interatores específicos desta isoforma. Cinquenta interatores específicos do C-
terminal da PPP1CC2 foram identificados por espectrometria de massa, 
sugerindo novos potenciais alvos para futura modulação. Um desses 
interatores (GPx4) foi posteriormente validado.  
Concluindo, este trabalho confirmou o potencial dos CPPs na entrega de 
sequências peptídicas que têm como alvo PPIs únicas do espermatozoide, 
clarificou o mecanismo de ação dos péptidos testados e identificou potenciais 
alvos para novos contracetivos masculinos. 
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abstract 
 
The large number of unintended pregnancies worldwide due to the non-use or 
failure of contraceptive methods and the fact that male contraceptives are 
limited to condom and vasectomy, highlight the urgent need for the 
development of new contraceptive methods. The mechanism of sperm motility 
acquisition in the epididymis constitutes an ideal target for new 
pharmacological male contraceptives since only the post-testicular sperm 
maturation is affected. It is known that protein phosphatase 1 subunit gamma 2 
(PPP1CC2), a PPP1 isoform only present in testes and sperm, is essential for 
sperm motility acquisition. Protein-protein interactions (PPIs) have emerged as 
a promising class of drug targets and cell-penetrating peptides (CPPs) 
represents a recognized intracellular delivery system to target PPIs. The main 
goal of this work is to modulate PPP1CC2 complexes and, consequently, 
spermatozoa motility using peptides covalently coupled to CPPs. The results 
showed that both peptides tested could modulate sperm motility with a short 
incubation period, generally increasing the number of immotile spermatozoa. 
Additionally, we demonstrated that the peptide sequence that mimics the 
interaction interface between PPP1CC2 and a sperm-specific interactor – A-
kinase anchor protein 4 (AKAP4) – disrupted the PPP1CC2-AKAP4 interaction, 
resulting in arrest of sperm motility. The peptide that mimics the 22 amino-acid 
C-terminus of PPP1CC2 possible acts by disrupting the interaction between 
PPP1CC2 and isoform-specific interactors. Fifty putative isoform-specific 
interactors of PPP1CC2 C-terminus were identified by mass spectrometry and 
one of them was further validated (GPx4), suggesting new targets for similar 
contraceptive agents.  
In conclusion, this work confirmed the potential of CPPs to deliver peptide 
sequences that target unique PPIs in spermatozoa, clarified the mechanism of 
action of the peptides testes and identified other potential targets for new male 
contraceptives. 
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1.  General Introduction and Aims 
 
1.1.  Spermatogenesis 
Spermatogenesis is a highly regulated process that takes place within the seminiferous 
tubules and consists in the development of a diploid spermatogonium into a highly 
specialized haploid male gamete [1]. This process includes mitotic and meiotic divisions 
as well as extensive morphological alterations [2], and can be divided in four steps: (i) 
self-renewal and differentiation of spermatogonia, (ii) meiosis, (iii) spermiogenesis and (iv) 
spermiation [3,4]. The first phase consists in self-renewal of A dark and A pale 
spermatogonia and differentiation of A pale spermatogonia through mitosis producing type 
B spermatogonia [5]. Type B spermatogonia divide mitotically originating primary 
spermatocytes [2]. On phase ii, spermatocytogenesis, the primary spermatocyte 
undergoes two meiotic cycles giving rise to haploid spermatids [2]. Spermiogenesis 
consists in the differentiation of the spermatid into a spermatozoon and includes a 
complex sequence of events. The acrosome and flagellum are developed, chromatin 
condensation occurs and histones are changed by protamines, the excess of cytoplasm is 
removed, development of the tail and reorganization of cellular organelles such as 
centrioles and mitochondria takes place [2,4]. At this point the spermatid can be released 
to the tubule lumen, a process designated by spermiation. This process is highly regulated 
by complex signaling mechanisms involving the hypothalamic-pituitary-gonadal axis, 
leading to the continuous production of spermatozoa starting from puberty through the 
reproductive life span of the male [4,6] (reviewed by Rossitto et al. [7]).  
In humans, spermatogenesis takes approximately 74 days [2] but Misell et al. (2006) have 
observed that the duration of spermatogenesis is very variable among individuals [8]. The 
duration of this process also varies between species, for example 35 days in the mouse 
and hamster, 41 days in wild boar [9], 40 day in pig and 47 to 48 in sheep [10]. 
 
1.2.  Spermatozoa 
The mammalian spermatozoa (Figure 1) consist of a head and a flagellum [11] and its 
length is specie-specific ranging between 50 µm (boar) to 90 µm (bull). In humans, it 
varies between 50 to 60 µm. Both head and flagellum are covered by plasma membrane 
[12].  
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1.2.1.  Head 
The sperm head comprises a nucleus and an acrosome surrounded by the plasma 
membrane [12]. The nucleus contains the condensed chromatin with the genetic 
information. The structure of chromatin changes dramatically during the final stages of 
spermiogenesis, when the DNA condensing core and linker histones are partially 
exchanged to protamines, positively charged DNA proteins that enable nuclear hyper 
condensation [13,14]. Despite the human sperm chromatin being tightly packaged by 
protamines, up to 4% of the DNA remains packaged by histones [15]. Infertile men have a 
higher sperm histone to protamine ratio when compared with fertile controls [16]. The 
nucleus is covered by a reduced nuclear envelope, from which the nuclear pore 
complexes have been removed during spermiogenesis, except for the redundant nuclear 
envelopes (RNEs) found in some species at the base of the sperm nucleus [17]. Sperm 
nucleus is protected by the perinuclear theca, forming a rigid shell composed of disulfide 
bond-stabilized structural proteins combined with various other proteins [18]. The 
acrosome is a Golgi-derived structure that covers two thirds of the anterior head surface 
[19]. The inner and outer membranes of the acrosome contain a dense acrosomal matrix 
that encloses a variety of proteases that are believed to digest a fertilization site in the 
zona pellucida. The equatorial segment (posterior acrosome) is a folded-over complex of 
perinuclear theca, inner and outer acrosomal membranes, which carries receptors 
involved in the sperm-egg fusion. [20].  
 
1.2.2.  Flagellum 
The flagellum is the longest part of the sperm and is a critical structure for motility. The 
major cytoskeletal components of the flagellum are the axoneme, fibrous sheath (FS) and 
outer dense fibers (ODF). While the axoneme function as the motor of the sperm, the FS 
and ODF modulate the frequency and pattern of flagellar beating [21]. The axoneme 
extends the full length of the flagellum and is composed by nine microtubule doublet 
surrounding a central pair of microtubules called a “nine-plus-two” complex [12,21]. The 
peripheral pairs are partially fused and the microtubules of the central pair are separated. 
A protein called nexin is responsible for the link of one microtubule doublet to another and 
dynein is connected to peripheral pairs to generate propulsion force in the flagellum [22].  
The flagellum is divided into connecting piece, mid-piece, principal piece and end piece 
[23,24]. The shortest part of the flagellum is the connecting piece that attach the head to 
the rest of flagellum [11,24]. The mid-piece is adjacent to the head and is characterized by 
the presence of a mitochondrial sheath (MS) that surrounds the axoneme and ODFs [12]. 
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While the MS is restricted to the mid-piece, the ODFs extend into the principal piece of the 
flagellum [25]. The annulus (or Jensen’s ring) marks the barrier between the mid-piece 
and principal piece and prevents a caudal displacement of the mitochondria during tail 
movement. The principal piece occupies nearly three-fourths of flagellum’s length and is 
flanked anteriorly by the mid-piece and posteriorly by a short distal piece [11]. At the start 
of the principal piece, the MS terminates and two of the ODFs are replaced by two 
longitudinal columns of fibrous sheet (FS). The most abundant protein present in the FS is 
A-kinase anchor protein 4 (AKAP4), a PKA-anchoring testis-specific protein [21,26]. The 
FS columns define the length of the principal piece and are stabilized by circumferential 
ribs that surround the ODFs [23]. Usually all of the ODF are thickest in the proximal part of 
the middle piece and progressively diminish in diameter from the base to the tip of the tail 
[12]. The FS is the only structure that is restricted to the principal piece. The end piece is 
a short segment at the tip of the flagellum where the axoneme is only surrounded by a 
plasma membrane [12].   
 
 
Figure 1 – Representation of the mammalian spermatozoa and the ultrastructure of the flagellum. (A) The 
flagellum is divided in four pieces: connection piece, middle piece, principal piece and end piece. The end of 
the middle piece and the start of the principal piece is demarcated by the annulus. (B) In a transversal cut 
through the middle piece is observed the plasma membrane (PM) and the mitochondrial sheath (MS) around 
nine outer dense fibers (ODF) and the axoneme. The axoneme is composed by nine outer microtubule 
doublets (OMDA) with associated dynein arms (DA) and radial spokes (RS) around a central pair of 
microtubules (CP). (C) Cross-section through the principal piece shows the PM surrounding seven ODF. The 
ODF 3 and 8 have been replaced by two longitudinal columns of fibrous sheath (FS) that are connected by 
transverse ribs (TR).  (D)The final piece shows only plasma membrane and the axoneme.  Adapted from [25]. 
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1.3.  Sperm Motility 
The human sperm is a notable cell, characterized for its small size, lack of most 
organelles, almost devoided of transcription and translation, high polarity and fast motility 
[21]. Sperm motility can be defined as a propagation of transverse waves along the 
flagellum in a proximal-to-distal direction producing an impulse that pushes the 
spermatozoon through the female genital tract to reach and penetrate oocyte [27,28]. 
According with Paoli and colleagues, sperm motility results of many complexes processes 
like oxidation of energy substrates, phosphorylation of proteins involved in signal 
transduction cascades and conversion of chemical into mechanical energy in the 
axoneme [27]. The flagellar beat appears to be regulated by ATPase activity of axonemal 
dynein arms and modulated by alterations on pH, adenosine triphosphate (ATP) 
availability, calcium concentration and phosphorylation but the mechanism is not 
completely understood [25]. 
The motility is only acquired in the epididymis, where these cells become mature [28]. 
Spermatozoa motility patterns differ between the ejaculate and the fertilization site, and 
have been defined as activated and hyperactivated motility respectively. Immotile or 
poorly motile sperm is generally accepted like a clinical sign of infertility and the main 
cause is frequently unknown. In fact, very little is known about the mechanisms involved in 
regulating sperm motility so more research is crucial [29]. 
 
1.3.1.  Epididymis and motility acquisition 
When spermatozoa leave the testis, are morphological mature but functionally inactive so, 
incapable of fertilize the female gamete. Functionality is acquired during post-testicular 
maturation via mechanisms that are involved in acquisition, loss or post-translation 
modification of proteins [30]. The first step of maturation occurs in epididymis, a tightly 
coiled, highly differentiated structure present in all mammals that connects the efferent 
ducts of the testis to the vas deferens. It can be divided into anatomically distinct 
segments or regions: (i) caput (head), (ii) corpus (body), (iii) cauda (tail). In mammals, the 
epididymis has numerous functions including reabsorption of the fluid secreted by the 
seminiferous tubules and the maturation and storage of sperm [31]. Several studies 
showed that caput epididymal spermatozoa are immotile and do not show any progressive 
motility or flagella beating but spermatozoa obtained from caudal epididymis are highly 
motile [32].  During sperm maturation in the epididymis several biochemical and 
morphological changes occurs, resulting in progressive motility [33]. Those includes 
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changes in pH, intracellular concentrations of calcium ions and cyclic adenosine mono-
phosphate (cAMP) that leads to shifts in protein phosphorylation status [30,34]. 
 
1.3.2.  Activated and hyperactivated motility 
There are two types of sperm motility patterns in most mammals: activated motility 
observed in the ejaculated spermatozoa and hyperactivated motility which is observed in 
spermatozoa at the site of fertilization [25,35,36] (Figure 2). Activated spermatozoa, show 
a symmetrical movement of flagellum and low-amplitude waveform that drives a sperm in 
a straight line in moderately non-viscous media such as seminal plasma [25,36]. This type 
of movement is acquired in epididymis and required in initial stages of sperm transport 
through the female reproductive tract [28]. This is regulated by phosphorylation 
mechanisms, being stimulated by phosphorylation in serine/threonine mechanisms [37].  
When sperm reach the oviduct, the pattern of flagellar beat changes to an asymmetrical 
movement and higher amplitude, which results in a circular trajectory also known as a 
figure-8 trajectory [36,38]. This is called hyperactivated motility and is necessary to sperm 
progression in the oviduct, dissociation with the oviduct epithelium and to assist sperm in 
penetrating the cumulus oophorous and zona pellucida [28,39]. Although hyperactivation 
generally occurs at some point during capacitation, the pathways leading to capacitation 
and hyperactivation are not the same [40]. The initiation and maintenance of this type of 
motility patter in vitro requires several physiological factors such Ca2+, bicarbonate and 
metabolic substrates [37,41].    
 
Figure 2 – Comparison of flagellar wave-forms of spermatozoa. Pictures of activated (A) and hyperactivated 
(B) hamster sperm from video records. Schematic representation of bending patterns of activated (C) and 
hyperactivated (D) morphological normal spermatozoa in low viscous medium. Adapted from [42]. 
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1.3.3.  Metabolic pathways to produce energy: oxidative phosphorylation 
and glycolysis  
ATP is one of the key requirements for sperm motility, acting as a molecular motor for the 
flagellar movement [27]. In fact, ATP is the fuel used for axonemal dynein ATPases within 
the flagellum and is required in both activated and hyperactivated motility [35]. Also 
protein modification, such as phosphorylation, depends on ATP so it is not surprising that 
sperm requires more ATP than most type of cells [43]. Two metabolic pathways have 
been suggested for ATP production: mitochondrial respiration and glycolysis. Although the 
energy required for sperm motility be manly produced by oxidative phosphorylation in 
mitochondria at the middle piece, glycolysis seems to be an important source of ATP 
along the flagellum, occurring in the head and principal piece of the flagellum [35,44]. 
Mutations or environmental factors which compromise the activity of glycolytic enzymes, 
like glyceraldehyde 3-phosphate dehydrogenase (G3PD) or phosphoglycerate kinase 2 
(PGK2), leads to a leak in energy production and then to immotile spermatozoa [45,46].  
 
1.4.  Role of Phosphoprotein Phosphatase 1 in sperm motility  
 
1.4.1.  Phosphoprotein Phosphatase 1 subunit gamma 2 
Phosphoprotein phosphatase is a superfamily of proteins phosphatases which 
dephosphorylates serine and threonine residues [47]. This superfamily includes PPP1 to 
PPP7  differing only in their N- and C- terminus and sharing high homology in the catalytic 
domains [48–50]. PPP1 is responsible for about a third of all protein dephosphorylation 
reactions that occur in eukaryotic cells and the catalytic subunit (PPP1C) is encoded by 
three different genes (PPP1CA, PPP1CB and PPP1CC) being involved in the regulation 
of several cellular events like glycogen metabolism, cell cycle, and sperm motility [51]. 
After transcription, PPP1CC undergoes tissue-specific splicing, originating a ubiquitously 
expressed isoform, PPP1CC1, and a testis-enriched and sperm-specific isoform, 
PPP1CC2. The difference between these isoforms resides strictly in the C-terminal [51]. 
All four isoforms are expressed in mammalian testis [52,53] but PPP1CC2 is the isoform 
in higher amount in testis and spermatozoa [54]. PPP1CC2 is predominantly localized in 
post-meiotic cells, in the cytoplasm of secondary spermatocytes, round spermatids and 
elongated spermatids [52,53]. Some authors have showed that this phosphatase is 
involved in sperm tail morphogenesis. Varmuza et al. (1999) showed that the Ppp1cc 
gene deletion in mouse testis causes loss of both isoforms (PPP1CC1 and PPP1CC2) 
and results in male infertility due to impaired spermatogenesis.  Disruption of Ppp1cc 
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result in malformed sperm tails, loss of mitochondrial sheaths and disorganized ODFs [55] 
as also showed by Chakrabarti and colleagues [52].  A recent study demonstrated that 
PPP1CC2, in the absence of PPP1CC1, restore sperm morphogenesis and sperm 
function in testis [56]. However, Soler and colleagues have observed that expression of 
transgenic PPP1CC2 in testis of Ppp1cc-null mice only restore spermatid viability and 
spermiation and not normal sperm tail morphology, motility or fertility [57]. 
 
1.4.2.  PPP1CC2 and sperm motility acquisition in epididymis  
Spermatozoa are specialized cells that are considered to be transcriptional inactive and 
incapable of synthetize new proteins so, protein phosphorylation is a post-translational 
mechanism that plays an important role in several events [58]. Protein phosphorylation is 
the net result of the action of protein kinases and phosphatases, and immotile sperm in 
the caput epididymis have significantly greater protein phosphatase activity than motile 
sperm in caudal epididymis [31].  
PPP1CC2 is the only PPP1 isoform present along the entire flagellum including the mid-
piece [59]. Since decreased PPP1CC2 activity is associated with increased motility, 
PPP1CC2 is thought to be a key protein for regulating sperm motility [52]. In fact, the 
inhibition of this protein activity in caudal sperm is connected to the onset of progressive 
motility and to a significant increase in vigorous movement in progressive motile sperm 
[33,60]. Okadaic acid and calyculin A are known PPP1 inhibitors and both initiate and 
stimulate motility in epididymal spermatozoa [33,60] and also promote hyperactivated 
sperm motility and acrosome reaction [42,61]. During epididymal sperm maturation the 
activity of PPP1 declines due to the lowering of its catalytic activity [62].  
 
1.4.3.  PPP1CC2 complexes in sperm motility 
PPP1 exists in the cell as an oligomeric complex in which the PPP1C subunit binds to one 
or two regulatory subunits known as PPP1 Interacting Proteins (PIPs) that modulate its 
cellular localization, substrate specificity and activity [63,64]. More than 200 PIPs have 
been identified and they can be divided into PPP1C inhibitors, substrates, substrate-
specifiers and targeting-subunits [63,65]. The binding of PIPs to PPP1C is mediated by 
short amino acid motifs and about 10 have already been described [66]. The best known 
PPP1 binding motif, is the RVxF, present in about 90% of all known PIPs and is thought to 
be the anchor for subsequent interactions [65]. The surface of PPP1 contains many 
binding sites for short PPP1-docking motifs that are combined by PIPs to create a PPP1-
binding code [66] that is universal (PPP1C binding motifs are conserved along evolution), 
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specific (PPP1C binding motif does not bind to any related Phosphatase), degenerated 
(the amino acids in the binding motifs may have some flexibility which generates different 
binding affinities), nonexclusive (binding to a PIP does not exclude binding to a second 
PIP if the binding motif is different) and dynamic (there is molar excess of PIPs in 
comparison to PPP1C) [65]. Thus, depending on the PIP that is bound to PPP1C, the 
complex formed is involved in a specific cellular task [51].  
PPP1CC2 activity during sperm maturation in the epididymis has been suggested to be 
mainly regulated by its inhibitors – PPP1R2 (inhibitor 2, I2), PPP1R7 (sds22) and 
PPP1R11 (inhibitor 3, I3) – by YWHA (14-3-3) and AKAPs [59] (Figure 3). Endophilin B1t, 
a testis enriched isoform of the somatic endophilin B1a, and the spermatogenic zip protein 
(Spz1) [67,68] are isoform-specific interactors. Both endophilin B1t and Spz1 do not 
interact with other PPP1C isoforms or with a truncated PPP1CC2 mutant lacking the 
unique C-terminus [67,68]. TMEM225, a protein predominantly localized to the equatorial 
segment in mature spermatozoa of mice, is also capable of bind to PPP1CC2 through 
RVxF motif and inhibit PPP1CC2. This evidence suggests that TMEM225 could regulate 
sperm motility and capacitation although its localization makes its contribution to motility 
less likely [69]. The role of these and other complexes in sperm motility still needs to be 
fully elucidated.  
1.1.1.1 PPP1CC2/PPP1R2/GSK-3 Complex 
PPP1R2 (I2) is a protein capable of inhibit the catalytic subunit of PPP1 leading to the 
production of a stable PPP1-PPP1R2 complex. Glycogen-synthase kinase (GSK)-3 is 
responsible for PPP1R2 phosphorylation at Thr73 resulting in the dissociation of PPP1 
and PPP1R2 and, then, PPP1 becomes active [58,60,70]. In fact, GSK3a knockout mice 
is infertile due to impaired sperm motility but revealed high activity of PPP1CC2 in sperm 
[70]. Some studies have identified a PPP1R2-like activity and the presence of GSK-3 in 
mammalian sperm. Immotile bovine caput epididymal sperm contains 2-fold higher levels 
of protein phosphatase activity, identified as being PPP1CC2, and 6-fold higher GSK-3 
activity than mature motile caudal sperm. Thus, the complex PPP1CC2/ PPP1R2-like is 
inactive in motile caudal sperm and the phosphatase activity is re-established in immotile 
sperm by the higher GSK-3 activity [33,60]. 
Korrodi-Gregório et al. have identified, by an yeast two-hybrid screen of a human testis 
library, a positive clone designated PPP1R2 pseudogene 3 (PPP1R3P3). PPP1R2P3 
protein binds directly to PPP1CC and the inactive PPP1CC2-inhibitor complex formed 
cannot be activated by GSK-3 phosphorylation because there is no site for GSK-3 
phosphorylation. PPP1R3P3 represents a constitutive inhibitor of PP1 that is independent 
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of GSK-3 phosphorylation [58]. One hypothesis might be that PPP1R3P3 is only present 
in caudal motile sperm, leading to constitutive inactivation of PP1CC2. Alternatively, 
PPP1R3P3 may be bound to a protein that keeps it from binding PP1CC2 in immotile 
caput sperm, paralleling what happens with PPP1R7 (sds22). The complex 
PP1CC2/PPP1R2/ GSK-3 may explain the unidirectional acquisition of sperm motility 
along the epididymal transit [59] and might be pre-requisites for the optimum function of 
spermatozoa [71]. 
 
 
Figure 3 - Schematic representation of the role of PPP1CC2 in the regulation of sperm motility acquisition. 
AKAPs anchoring modulate PPP1CC2 and PKA activities regulating phosphorylation events. In caput 
epididymis, PPP2CA is phosphorylated and consequently active, which in turn dephosphorylated GSK3 that 
becomes active too. GSK3 phosphorylates PPP1R2 (I-2) which inhibits the interaction between PPP1R2 and 
PPP1CC2 resulting in active PPP1CC2, and consequently, immotile spermatozoa. PPP1R7 (sds22) is unable 
to inhibit PPP1CC2 since it is bound to p17. In caput epididymis, active PPP1 results in protein 
dephosphorylation and then immotile spermatozoa. In caudal epididymis, the inhibition of PPP2CA and the 
binding of Wnt to LRP6 receptor results in increasing of GSK3 serine phosphorylation leading to GSK3 
inhibition. The inhibition of GSK3 leads to decrease of Thr73 PPP1R2 phosphorylation. Consequently, 
PPP1R2 binds PPP1. PPP1 is also bound to PPPP1R2P3 (I-2L) that cannot be phosphorylated by GSK3. A 
multimeric complex has been identified composed by PPP1CC2, PPP1R7, actin and PPP1R11 (I-3), where 
PPP1CC2 was inactive. Thus, PPP1 activity is inhibited leading to motile spermatozoa. Phosphorylated GSK3 
and phosphorylated PPP1CC2 are bound to YWHA (14-3-3) in caudal sperm. P, phosphorylated; M, 
methylated. Adapted from [59].  
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1.1.1.2 PPP1CC2/PPP1R11/PPP1R7 Complex 
PPP1R11 (I3), a human homologue of the t-complex expressed protein 5 (Tctex5) present 
in mouse [72], is a heat-stable PPP1 inhibitor protein [73] located in the head and principal 
piece of the tail (Figure 4). This protein has been linked to male infertility phenotypes of 
impaired sperm tail development and poor sperm motility [71,74]. PPP1R7 is a yeast 
sds22 homologue identified in caudal spermatozoa as a regulator of PP1CC2 activity [75–
77]. In contrast, PP1CC2 and sds22 do not interact in caput bovine sperm. In male germ 
cells, PPP1CC2, PPP1R2, PPP1R7 and actin form a multimeric complex in which 
PPP1CC2 seems to be inactive [78]. Additionally, PPP1R7 has consensus sites for 
phosphorylation by GSK-3, protein kinase-A (PKA) and calmodulin dependent kinase II, 
all present in sperm [59]. It is possible that PP1CC2 activation and inactivation, due to its 
binding and dissociation from sds22, might be part of the mechanisms regulating motility 
and other sperm functions but its role needs to be further elucidated.   
1.1.1.3 PPP1CC2/YWHA Complex  
PPP1CC2 has at the C-terminus a consensus TPPR amino acid sequence containing a 
threonine residue (T320) that can be phosphorylated by cyclin-dependent kinases (CDKs) 
[79,80], like CDK2 [34]. The amount of phosphorylated PP1CC2 increases during sperm 
epididymal maturation and is located in equatorial region of the head and the principal 
piece of the tail [34]. In caudal spermatozoa, only phosphorylated PPP1CC2 exists. The 
regulation of PPP1CC2 by CDK2 could be achieved through the binding of PPP1CC2 to 
the bridging molecule 14-3-3 (YWHA) [81]. YWHA isoform is a highly conserved family of 
acidic proteins, expressed in many eukaryotic cells, that regulate processes such as cell 
cycle, apoptosis, protein trafficking, metabolism and transcriptional regulation of gene 
expression [71]. This protein, in mature spermatozoa, is present in the post-acrosomal 
region of the head and the principal piece [81] (Figure 4) and binds to PPP1CC2 when 
phosphorylated, regulating its catalytic activity, phosphorylation or interaction with other 
proteins [71]. GSK3 also binds to YWHA [82].  
1.1.1.4 PPP1CC2/AKAP/PKA Complex 
Several studies suggest that PPP1/AKAP/PKA complex is essential for sperm motility 
regulation. Cyclic AMP (cAMP) analogues and phosphodiesterase inhibitors increase the 
motility of mature spermatozoa. It has been proposed that elevated cAMP stimulates the 
phosphorylation of sperm proteins by PKA leading to increased motility [83]. Furthermore, 
anchoring of PKA through AKAPs to distinct intracellular sites in sperm is believed to be 
essential for regulating sperm motility since disruption of the AKAP–PKA interaction 
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results in motility arrest [84].  AKAPs function by target the cAMP-dependent PKA to 
various subcellular locations via the regulatory subunits of the kinase [85]. To date, more 
than 40 AKAPs have been identified, three of them associated with PPP1CC2 (AKAP220, 
AKAP3 and AKAP4) [85–87] in testis/sperm. AKAPs and PPP1CC2 are both present in 
the flagellum, so they might be involved in motility acquisition [22,86].  
AKAP220/AKAP11 binds PKA and PPP1, inhibiting the phosphatase [88]. AKAP220 
mRNA is expressed at high levels in human testis and in isolated human pachytene 
spermatocytes and round spermatids. In human germ cells and mature sperm, AKAP220 
is located in the mid piece and associated with cytoskeletal structures [87]. The AKAP220 
associated to the mid piece could serve to anchor PKA and/or PPP1CC2, regulating the 
contractile machinery in the sperm axoneme. It has also been showed that disruption of 
RII-AKAP interaction by peptides is responsible for the arrest of sperm motility [84].  
AKAP3 (or AKAP 110) is a testis-specific protein found only in the fibrous sheath and 
located to the circumferential ribs of human sperm [23,85]. This protein binds to the RII 
subunit of PKA. AKAP3 binds to PDE4A (phosphodiesterase 4A cAMP specific) 
potentially controlling PKA activity [59]. Specific inhibitors of PDEs increase the motility of 
the cell, and PKA-anchoring inhibitor peptides arrest sperm motility [84]. 
AKAP4 (originally called AKAP82) is only expressed in testis and is the major protein in 
the fibrous sheath [85]. The transcription of this AKAP is initiated 20-22 days after birth 
and the mRNA is present in spermatids but not in pachytene spermatocytes [26]. A 
targeted disruption of the Akap4 gene causing defects in mice sperm flagellum through 
the lack of fibrous sheath of the principal piece affecting male mice fertility was also 
demonstrated by Miki et al. [21]. Additionally, Akap4 gene knockout in mice changes the 
activity and phosphorylation of PPP1CC2, as demonstrated by Huang and colleagues 
[89]. This suggests that AKAP4 is required to regulate the phosphorylation levels of 
PPP1CC2 in the principal piece of the spermatozoa.  
These findings suggest that the PPP1CC2/AKAP/PKA complex is important for regulation 
of sperm motility and the loss of PPP1CC2-AKAP4 interaction results in immotile 
spermatozoa. Sperm-specific AKAPs seem to be a very directional target for the 
development of male contraceptives or for infertility therapeutics. 
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Figure 4 – Schematic representation of subcellular localization of protein phosphatase and interacting proteins 
(PPP1-PIP) complexes in spermatozoa. AKAP, A-kinase anchoring protein; GSK-3, glycogen synthase 
kinase-3; PKA, Protein kinase A. Adapted from [59].  
 
1.5.  Cell-Penetrating Peptides and their clinical potential  
The cell uses different mechanisms, such as post-translation modifications (PTMs) and 
protein-protein interactions (PPI), to regulate its signal cascades. One of the most 
commons PTMs that occur in the cell is phosphorylation, corresponding to chemical 
alterations in the protein structure that change its structural conformation and the 
accessibility between enzymes and interacting proteins [90]. On the other hand, PPIs are 
defined as “physical contacts with molecular docking between proteins that occur in a cell 
or in a living organism in vivo” [91]. These interactions can be permanent, when a stable 
complex is formed, or transitory, when is involved in signaling pathways. Not all possible 
interactions occur in any cell at any time. In fact, interactions depend on the biological 
context, such cell type, cell cycle phase, development stage, environmental conditions, 
protein modifications, presence of cofactor and presence of other binding partners [92]. 
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In the past two decades, PPI have emerged as promising drug targets and the field is 
evolving fast [93]. Several approaches have been used to modulate PPIs, in particular 
those based on the use of small organic molecules derived from natural compounds or 
organic synthesis [94]. Recombinant proteins/antibodies and peptides can explore large 
surfaces and, thus, being excellent PPI modulators. Peptides in particular have several 
advantages like: (i) adaptability to larger surfaces due to their flexibility, (ii) easy 
modularity, which increases structural diversity allowing for higher selectivity and potency, 
(iii) accumulation only in a minor extent in tissues and (iv) biocompatibility, which means 
low toxicity in humans [95]. However, peptides are difficult to convert into oral drugs, they 
are not metabolically stable undergoing rapid removal by hepatic and renal clearance, 
they do not cross physiological barriers easily and they have poor oral bioavailability, due 
the digestion by proteases for example. Fortunately, peptides can be easily synthetized 
and modified to improve their stability, permeability and bioavailability [96].  
Cell-penetrating peptides (CPPs) are a class of cellular delivery vectors and are reliable 
vehicles for the intracellular delivery of therapeutic agents [96]. CPPs are short peptide 
sequences, consisting of less than 30 amino acids in length and often carry a positive 
charge, that can pass through the cellular membrane and deliver different types of cargo 
that are usually unable to cross an intact lipid barrier [94,97] (Figure 5). 
 
Figure 5 – Principle of cell-penetrating peptide targeting and delivery. (A) A homing peptide (HP) has no 
inherent internalization properties and only delivers its cargo to specific cell-surface receptors. (B) A HP 
conjugated with cell-penetrating peptides (HP-CPP) undergoes receptor binding and undergoes cargo 
internalization via endocytosis or pore formation. Adapted from [98].  
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The peptides are usually classified according to their physicochemical properties into 
cationic, amphipathic, hydrophobic and anionic categories [97,99] or according to their 
origin in: 1) a polypeptide motif derived from natural proteins with penetrating functions, 2) 
an artificially designed and synthetic polypeptides which are optimized as molecular-
internalizing vectors or 3) a chimeric sequence [94]. The first two CPPs described, 
penetratin and Tat peptide, are cationic stretches of amino acids identified in the primary 
sequences of both insect- and virally-encoded transcription factors, respectively [96]. 
These polycationic CPP motifs confer their native proteins the capacity to cross biological 
membranes to achieve their role as transcriptional activators. Similar CPP sequences 
have been also identified in several human proteins [96]. Today, the class of CPPs 
includes numerous amino acid sequences that can be broadly divided into tissue-specific 
and non-tissue specific peptides [100,101] (Table 1). The identification of intrinsically 
bioactive CPPs emphasizes the tremendous clinical potential of CPP technologies [102]. 
In terms of clinical applications, CPP can potentially be used to deliver a wide range of 
therapeutic moieties, including small molecules, liposomes, nanoparticles and 
biopharmaceuticals including oligonucleotides, peptides and proteins [102,103]. 
Table 1 – Examples of some common cell-penetrating peptides and their applications. 
Name Sequence Source Cargo 
Cationic 
Tat [104] 
 
Penetratin [105] 
 
Polyarginine [106] 
 
8-Lysine [107] 
PTD-4 [108] 
PTD-5 [108] 
Oct4 [109] 
WT1-pTj [110] 
DPV3 [111] 
M918 [112] 
 
GRKKRRQRRRPPQ 
 
RQIKIWFQNRRMKWKK 
 
Rn (n =6–12) 
 
KKKKKKKK 
YARAAARQARA 
RRQRRTSKLMKR 
DVVRVWFCNRRQKGKR 
KDCERRFSRSDQLKRHQRRHTGVKPFQ 
RKKRRRESRKKRRRES 
MVTVLFRRLRIRRACGPPRVRV 
 
HIV Tat protein 
 
Antennapedia 
homeodomain 
 
 
  
 
 
Oct4 protein 
Wilms tumor protein 1 
Heparin binding protein 
Tumor suppressor 
protein p14ARF 
 
Gene vectors, 
proteins, peptides, 
label 
Gene vectors, 
proteins, peptides, 
label 
Gene vectors, 
liposomes, label 
 
 
 
Protein, label 
Label 
Proteins 
Proteins and nucleic 
acids  
Hydrophobic 
Transportan [113] 
MAP [114] 
TP10 [115] 
Pep1 [116–118] 
 
KW [119] 
 
GWTLNSAGYLLGKINLKALAALAKKIL 
KLALKLALKALKAALKLA 
AGYLLGKINLKALAALAKKIL 
KETWWETWWTEWSQPKKKRKV 
 
KRKRWHW 
 
Galanin and mastoparan 
 
Galanin and mastoparan 
SV 40 NLS and a 
hydrophobic domain 
 
 
Gene vector, label 
Label 
 
Proteins, gene vectors 
 
Small molecules 
Amphipathic  
Azurin p18 [120] 
Azurin p28 [121] 
hCT18-32 [122] 
pVEC [123] 
VP22 [124,125] 
 
C105Y [126–128] 
 
JTS1 [129] 
VT5 [130] 
Mastoparan [131] 
 
LSTAADMQGVVTDGMASG 
LSTAADMQGVVTDGMASGLDKDYLKPDD 
KFHTFPQTAIGVGAP 
LLIILRRRIRKQAHAHSK 
NAATATRGRSAASRPTQRPRAPARSASRP
RRPVQ 
CSIPPEVKFNKPFVYLI 
 
GLFEALLELLESLWELLLEA 
DPKGDPKGVTVTVTVTVTGKGDPKPD 
INLKALAALAKKIL 
 
Azurin 
Azurin 
Calcitonin 
VE-cadherin  
Herpes simplex virus 
envelope protein 
α1-Antitrypsin 
 
 
 
 
 
 
 
 
Proteins, fluorophores 
 
 
Gene vector, peptide, 
liposome 
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Name Sequence Source Cargo 
Mitoparan [131] INLKKLAKL(Aib)KKIL  Voltage-dependent 
anion channel 
CPPs-tissue specific     
CTP [132] 
K5-FGF [133] 
 
HAP-1 [134] 
293P-1 [135] 
APWHLSSQYSRT 
AAVALLPAVLLALLP 
 
SFHQFARATLAS 
SNNNVRPIHIWP 
Phage display  
Kaposi fibroblast growth 
factor 
Phage display 
Phage display 
 
Peptides, antibodies  
Others  
Nosangiotide [102] 
Camptide [102] 
Cyt c 77-101 [136] 
 
RKKTFKEVANAVKISA 
RKLTTIFPLNWKYRKALSLG 
GTKMIFVGIKKKEERADLIKKA 
 
 
 
Cytochrome c 
 
Two approaches are generally applied when CPPs are employed as delivery vectors: 
covalent conjugation (sychnologic pattern) and physical complexation (rhegnylogic 
pattern) [97]. A sychnologically organized CPP could include CPP joined to a bioactive 
peptide in which every amino acid side-chain is a message pharmacophore. The linker 
joining these two distinct peptides as a tandem structure can be a conventional peptide 
bond, a disulphide or other covalent structure. In the rhegnylogic organization the 
pharmacophores for penetration (address) and bioactivity (message) are discontinuously 
distributed within a single peptide [102] (Figure 6). 
 
Figure 6 - Bioactive peptides can be delivered as a sychnologically-organized chimera conjugated to CPPs or 
as a rhegnylogic organization. In this conceptual diagram the pharmacophores responsible for penetration are 
illustrated in blue, whereas those conferring bioactivity are colored purple. Adapted from [102]. 
 
CPP internalization may be achieved by both direct plasma membrane translocation and 
energy-dependent endocytic mechanisms that depends on cell type, CPP concentration 
and size and nature of the conjugated cargo [96,99]. Several types of endocytosis have 
been demonstrated for different peptides, including caveolar, clathrin-mediated and 
micropinocytosis [99]. The mechanism of uptake is highly dependent on the type of cargo, 
making it difficult to predict which penetrating peptide should be selected in each case. 
The CPP technology have numerous advantages which include low toxicity, more precise 
target-specificity and routes of administration that may be relatively non-invasive [96,98]. 
Compared with other traditional techniques, such as microinjection or electroporation, 
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CPPs do not destroy the integrity of cell membranes and are considered high efficient and 
safe [94] and also can be vectors for the delivery of peptides across epithelia and the 
blood-brain barrier [97].  
CPP-mediated delivery of peptides and proteins has been successfully applied to target 
cancer, muscular dystrophy, cardiology, prion diseases, to treat systemic and local 
inflammations resulting from invasion by pathogens or a chemical or physical injury and 
have also been applied to induce generation of pluripotent stem cells as a safer strategy 
than the classical method involving introduction of viral genetic material [97,137]. 
Recently Jones and colleagues demonstrated that CPPs are able of translocate into the 
sperm cell and modulate sperm physiology and function without affecting its viability and 
motility [138]. Another study demonstrates that CPPs accumulate differentially at distinct 
structural compartments within spermatozoa [139]. In fact, Tat accumulates within the 
spermatozoa head, including the acrosome, Mitoparan (MitP) demonstrates a propensity 
for mitochondrial localization and C105Y accumulates in all structures of sperm except the 
interior head and acrosome [139].   
In the present study, three peptide sequences derived from (i) the 22 amino acid C-
terminus of the human PPP1CC2 
(303KPNATRPVTPPRVASGLNPSIQKASNYRNNTVLY336) [PPP1CC2-CT], (ii) the 
region including the PPP1 binding motif (40KVICF44) of the human AKAP4 
(33GQQDQDRKVICFVDVSTLNV52) [AKAP4-BM] and (iii) a mutated homologue 
(33GQQDQDRAAAAAVDVSTLNV52) [AKAP4-BM M] previously synthesized using 
microwave-assisted solid-phase peptide synthesis were used. These endogenous 
sequences and structural analogues were coupled to penetratin 
(RQIKIWFQNRRMKWKK), an inert CPP (Table 2). 
 
Table 2 - Peptide sequences, abbreviation and molecular masses. Underlined, penetratin (CPP); Bold, PPP1 
binding motif (pattern: [RK]-X(0,1)-[VI]-{P}-[FW]). 
Peptide 
designation Abbreviation  Peptide sequence Mass (g/mol) 
PPP1CC2 C-
terminal1 PPP1CC2-CT 
NH2- 
RQIKIWFQNRRMKWKKKPNATRPVTPPRVASGLNPSI 
QKASNYRNNTVLY-H 
5953,0124 
AKAP4 binding 
motif AKAP4-BM 
H-
KKWKMRRNQFWIKIQRVNLTSVAVFCIVKRDQDQQG 
-NH2 
4448,3148 
AKAP4 binding 
motif mutant AKAP4-BM M 
H-
KKWKMRRNQFWIKIQRVNLTSVAVAAAAARDQDQQ 
G-NH2 
4212,9217 
1The last amino acid of PPP1CC1 C-terminus (glutamic acid) was excluded due to its negative charge. 
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1.6.  Aims 
World’s population has been rising and it is expected that it will reach 9-10 billion by 2050. 
This population growth is a leading cause of environmental degradation and human 
suffering from poverty [140]. Despite the currently available contraceptive methods, the 
number of unintended pregnancies worldwide is still high. Contraceptive nonuse, incorrect 
use and failure result in over than 20% of pregnancies ending in abortion [141,142] and 
unplanned children are often exposed to poverty and neglect environments. Unplanned 
birth may also have serious health, economic and social consequences for families [143]. 
These statistics reflect the need for new contraceptive methods to overcome the problem 
of unintended pregnancy, abortion and uncontrolled fertility. Compared with female, male 
contraceptive methods are few and underused. According the United Nations, in 2015, 
only 12% of couples used condom, being preferentially used female contraceptives such 
as pill and intra-uterine device. The development of new contraceptives has focused upon 
hormonal modulation, however, this technology had several side effects [140,144,145]. 
The mechanism of spermatozoa motility acquisition is a perfect target for a new male 
contraceptive since normal hormone and spermatozoa production occur and only the 
post-testicular sperm maturation is affected.     
Thus, the main goal of this study is to modulate protein complexes in spermatozoa and, 
consequently, sperm motility using cell-penetrating peptides that specifically interact with 
non-hormonal targets selectively expressed in testis and sperm. To that, we proposed to: 
1. Evaluate the concentration- and time-dependent intracellular uptake of the cell-
penetrating peptides in spermatozoa; 
2. Evaluate the impact of the cell-penetrating peptides on spermatozoa motility; 
3. Evaluate the disruptive potential of the AKAP4-BM peptide on the AKAP4-
PPP1CC2 interaction;  
4. Characterize the interactome of the PPP1CC2-CT peptide in spermatozoa.  
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2. Material and Methods  
 
Experimental procedures were performed in Signal Transduction Laboratory, Institute 
for Research in Biomedicine (iBiMED), University of Aveiro (Aveiro, Portugal). The 
details of the solutions used in this thesis are stated in the Supplementary Table 1. 
 
2.1.  Sample processing 
This study was approved by the Ethics and Internal Review Board of the Hospital 
Infante D. Pedro E.P.E. (Aveiro, Portugal) and was conducted in accordance with the 
ethical standard of the Helsinki Declaration. Ejaculated human semen samples from 
volunteer donors were collected by masturbation into a sterile container. All donor 
signed an informed consent allowing the use of the samples for scientific proposes. 
Basic semen analysis was conducted in accordance with World Health Organization 
(WHO) guidelines [146] and only normal sperm samples were used. Briefly, after 
complete liquefaction of the semen samples at 37˚C, during approximately 30 minutes, 
a macroscopic examination was performed. The microscopic examination included the 
analysis of spermatozoa motility, concentration and morphology. All microscopy 
analyses were performed using a Zeiss Primo Star microscope (Carl Zeiss AG, 
Germany). The results of basic sperm analysis were detailed in Supplementary Table 
2. Frozen semen from bulls was obtained from LusoGenes, LDA (Aveiro, Portugal). 
Bovine semen was thawed in a 37°C water bath for 1 min. Human and bovine 
spermatozoa were isolated and washed three times from seminal plasma by 
centrifugation (600g for 10 min at room temperature) using ALLGrad Wash medium 
(LifeGlobal, Brussels, Belgium). Pellet was re-suspended in medium to a final 
concentration desired and incubated at 37°C with 5% CO2 until the appropriated 
treatments were added. The concentration of sperm cells after the washing procedures 
was assessed using the Sperm Class Analyzer CASA System (Microptic S L, 
Barcelona, Spain) with SCA® v5.4 software. Samples and controls (2 μl) were loaded 
into individual chambers of Leja Standrat Count 8 chamber slide 20 μm depth (Leja 
Products B. V., The Netherlands) which were pre-heated at 37°C. 
 
2.2.  Quantitative uptake analysis 
For the temporal-dependent quantitative uptake analysis of the competition peptides, 5 
million of bovine spermatozoa were incubated with 5 µM TAMRA-labeled peptides for 
15, 30 and 60 min at 37°C in a humidified atmosphere of 5% CO2. For the 
2. Material and Methods 
20 
concentration-dependent quantitative uptake analysis of the competition peptides, 5 
million of bovine spermatozoa were incubated with 5 µM, 7,5 µM and 10 µM TAMRA-
labeled peptides for 15 min at 37°C in a humidified atmosphere of 5% CO2. In both 
cases, after incubation with the peptides, the peptide containing solution was removed 
by centrifugation (600g for 10 min) and the pellet was washed two times with 200 µl of 
phosphate buffered saline (PBS) (600 g for 5 min). Cells were detached with 300 µl of 
1% (wt/vol) trypsin at 37°C, collected by centrifugation at 3000 g and lysed in 300 µL 
0.1 M NaOH for 2h on ice. 250 µL of each cell sample lysate were transferred to a 
black 96-wells plate and analyzed using an Infinite® 200 PRO (Tecan, Switzerland) 
(λAbs 544 nm/λEm 590 nm). 
2.3.  Motility assays 
To perform the motility assays, 20 million of sperm cells per treatment/well were used 
in a final volume of 250 µl. Sperm cells were incubated with 5 µM and 10 µM of the 
peptides (PPP1CC2-CT, AKAP4-BM and AKAP4-BM M). Control samples included 
sperm cells in medium. Samples and controls were incubated during 15 min at 37°C in 
a humidified atmosphere of 5% CO2. The influence on sperm motility parameters was 
assessed using the Sperm Class Analyzer CASA System (Microptic S L, Barcelona, 
Spain) with SCA® v5.4 software. Samples and controls (2 µl) were loaded into 
individual chambers of Leja Standart Count 8 chamber slide 20 µl depth (Leja Products 
B V, The Netherlands) pre-heated at 37ºC. This temperature was maintained while at 
least 700 sperm cells per measurement were evaluated. Each peptide was testes on 
samples from three different bulls and all the conditions were performed in triplicate.    
2.4.  Antibodies 
Homemade anti-PPP1CC2 antibody was used for Western Blot and 
immunoprecipitation studies. Primary antibodies used for Western Blot are summarized 
in Table 3. The infrared IRDye®680RD anti-rabbit (926-68071) and IRDye®800CW 
anti-mouse (926-32210) secondary antibodies (1:5000) were obtained from LI-COR 
Biosciences (Lincon, NE, USA).   
Table 3 – Primary antibodies used for Immunoblot. 
Antibody Host Dilution Molecular Weight (kDa) Reference Supplier  
Anti-PPP1CC2 Rabbit 1:2000 ~37 G502 Homemade 
Anti-AKAP4  Rabbit 1:300 ~94 Ab123415 Abcam 
Anti-AKAP4 Mouse 2,5 µg/ml ~94 ab56551 Abcam 
Anti-GPX4 Rabbit 1:1000 ~20 ABC269 Millipore  
Anti-β-tubulin Mouse 1:2000 -50 32-2600 Invitrogen 
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2.5.  Co-immunoprecipitation of PPP1CC2  
For the detection of PPP1CC2/AKAP4 interaction, 40 million of human sperm cells 
(volunteer 1, Supplementary Table 2) per condition were lysed in 1000 µl of 1x RIPA 
buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM 
EDTA) (Millipore Iberica S.A.U., Madrid, Spain) supplemented with protease inhibitor (1 
mM PMSF) for 30 minutes on ice and centrifuged at 16000 g for 15 min at 4ºC. 
For the competition assays, 20 million of human (volunteers 2 and 3, Supplementary 
Table 2) or bovine spermatozoa were incubated with 10 µM and 50 µM of AKAP4-BM 
and AKAP4-BM M peptides for 15 min. The peptide containing solution was removed 
(600g for 5 min) and sperm cells were lysed in 1000 µl 1x RIPA buffer (0.5 M Tris-HCl, 
pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA) (Millipore 
Iberica S.A.U., Madrid, Spain) supplemented with protease inhibitor (1 mM PMSF) for 
1h on ice and centrifuged at 16000 g for 10 min at 4ºC. Ninety percent of the 
supernatant was used for the subsequent steps (sperm soluble fraction). Ten percent 
of the soluble fraction was saved and the pellet (insoluble fraction) was re-suspended 
in 1000 µl 1% sodium dodecilsulfate (SDS) (sperm insoluble fraction). 
RIPA supernatant extracts were pre-cleared using 20 µl of Dynabeads® Protein G (Life 
Technologies AS., Madrid, Spain) per condition, during 30 min at 4ºC with rotation. An 
indirect co-immunoprecipitation approach was performed using 2 µg of homemade 
rabbit anti-PPP1CC2 overnight at 4ºC with rotation. 100 µl of beads were posteriorly 
added to the extracts and incubated 2 hours at 4ºC with rotation. After incubation, the 
supernatant was removed to a new microtubule and stored (unbound IP fraction) and 
the beads were washed two times with 500 µl PBS during 15 min at 4ºC with rotation. 
After washing, the beads were re-suspended in 1x loading buffer and boiled for 5 
minutes. The eluted fraction was then collected (IP fraction). 
2.6. Co-immunoprecipitation of biotinylated PPP1CC1-CT 
peptide 
To identify the interactome of the PPP1CC2-CT peptide in human spermatozoa, a co-
immunoprecipitation of the biotinylated PPP1CC2-CT peptide was performed. 15 
million of human sperm cells (volunteers 4 to 6, Supplementary Table 2) were 
incubated with 5 µM of biotinylated PPP1CC2-CT peptide for 15 min at 37°C in a 
humidified atmosphere of 5% CO2. The peptide containing solution was removed (600g 
for 15 min) and sperm cells were lysed in 250 µl of 1x RIPA buffer (0.5 M Tris-HCl, pH 
7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA) (Millipore Iberica 
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S.A.U., Madrid, Spain) supplemented with protease inhibitor (1 mM PMSF) for 30 min 
on ice and centrifuged at 16000g for 15 min at 4ºC. Ninety percent of the supernatant 
was used for the subsequent steps (sperm soluble fraction).  Ten percent of the soluble 
fraction was saved and the pellet (insoluble fraction) was re-suspended in 250 µl 1% 
SDS (sperm insoluble fraction). 50 µl per condition of Dynabeads® M-280 Streptavidin 
(Life Technologies AS., Madrid, Spain) were added to the RIPA supernatant extracts 
and incubated for 30 min at room temperature with gentle rotation. After incubation, the 
supernatant was removed to a new tube and stored (unbound IP fraction) and the 
beads were washed three times with 1 ml 1X PBS (for western blot) or with 1 ml trypsin 
digestion buffer (20 mM Tris-HCl pH 8.0, 2 mM CaCl2) (for LC-MS/MS). After washing, 
the beads were re-suspended in 30 µl LB 1X (for western blot) or in 150 µl trypsin 
digestion buffer (20 mM Tris-HCl pH 8.0, 2 mM CaCl2) (for LC-MS/MS at VIB 
Proteomics Core, Gent, Belgium) and stored at -20C.   
2.7.  Western Blotting  
The extracts were resolved by 10% or 15% SDS-polyacrylamide gel electrophoresis 
(PAGE) and proteins were electrotransferred onto nitrocellulose membranes. The gel 
was run at 200 V and electrotransferred at 200 mA for 2 hr. Non-specific protein-
binding sites on the membrane were blocked with 5% bovine serum albumin (BSA) in 
Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1h. The blots were then 
washed with TBST and incubated with primary antibodies (rabbit anti-PPP1CC2 or 
anti-β-tubulin for 1h at room temperature and rabbit anti-AKAP4, mouse anti-AKAP4 or 
rabbit anti-GPX4 overnight at 4ºC). After the incubation, the blots were washed three 
times for 10 min each with TBST and then incubated with the appropriate secondary 
antibody for 1h at room temperature. Blots were washed three times for 10 min with 
TBST and once with Tris-buffered saline (TBS: 25 mM Tris-HCl, pH 7.4, 150 mM NaCl) 
and immunodetected using the Odyssey Infrared Imaging System (LI-COR® 
Biosciences, US). 
2.8.  Cell culture 
HeLa cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) 
medium supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics (1% 
penicillin/streptomycin mixture). Cells were grown in 10 cm plates in a 5% CO2 
humidified incubator at 37ºC and sub cultured every 2-3 days.  
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2.9.  Cell transfection  
Lipofectamine®2000 was used for transfection of HeLa cells using the pCMV6-AC-
GFP-AKAP4 or pEGFP-N1 expression vectors. One day before transfection, 1 x 105 
cells were plated in 10 ml of DMEM medium supplemented with 10% FBS without 
antibiotics so they were 70-90% confluent at the time of transfection. For each 
transfection sample in 10 cm plates the DNA/lipofectamine complexes were prepared 
as follows: 50 µl of lipofectamine® 2000 were diluted in 1450 µl of Opti-MEM®I 
medium without serum and added to 20 µg of plasmid DNA previously diluted in 1500 
µl of the same medium. The mixture was allowed to complex for 20 min at RT and then 
3 ml of the complex were added to each plate containing cells and medium mixing 
gently by rocking the plate back and forth. 24h after incubation at 37ºC in a CO2 
incubator, transfected cells were washed twice in 1X PBS and cell extracts were 
prepared. 1.5 ml of SDS 1% were added to each plate and cells were collected with a 
scrapper. Lysed cells were centrifuged at 16 000g for 20 min and sonicated three times 
for 10 sec. Extracts were mass normalized using the bicinchoninic acid (BCA) assay 
(Fisher Scientific, Loures, Portugal). Sample were prepared to be assayed with 5 L of 
each sample plus 20 L of 1% SDS. Standard protein concentrations were prepared as 
described in Supplementary Table 3. Samples and standards were prepared in 
duplicate. The BSA stock solution used had a concentration of 2 mg/ml. The Working 
Reagent (WR) was prepared by mixing BCA reagent A with BCA reagent B in the 
proportion of 50:1. Then, 200 µl of WR was added to each well (standards and 
samples) and the plate was incubated at 37 ºC for 30 min. Once the tubes cooled to 
RT the absorbance was measured at 562 nm using an Infinite® 200 PRO (Tecan, 
Switzerland). A standard curve was obtained by plotting BSA standard absorbance vs 
BSA concentration, and used to determine the total protein concentration of each 
sample. 
 
2.10.  Membrane overlay 
HeLa cells extracts were resolved by 10% SDS-PAGE and proteins were 
electrotransferred onto nitrocellulose membranes. 30 µg of protein were loaded per 
condition/well. The gel was run at 200 V and electrotransferred at 200 mA for 2 hr. The 
membranes were cut and only the top part were overlaid with: (i) 10 pmol purified 
PPP1CC2 and 50 pmol AKAP4-BM peptide; (ii) 10 pmol purified PPP1CC2 and 50 
pmol AKAP4-BM M peptide; (iii) 10 pmol purified PPP1CC2 and (iv) 10 pmol purified 
PPP1CC2 and 25 pmol I-2. The incubations were performed in microtubes. The 
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membranes were blocked with 3% BSA in TBS for 30 min at room temperature. The 
purified PPP1CC2, the peptides (AKAP4-BM and AKAP4-BM M) and the I-2 were 
added to 1 mL of 3% BSA in TBS and allowed to incubate 15 min at 4ºC with gentle 
rotation. After blocking, the membranes were incubated with the corresponding 
conditions for 2 hours at room temperature with slow agitation. The membranes were 
then washed twice with TBST 1X for 10 min to remove the excess of protein and 
peptide and incubated with homemade rabbit anti-PPP1CC2 antibody (1:2000) for 1h 
at room temperature. After the incubation, the blots were washed three times for 10 
min each with TBST and incubated with an Infrared IRDye-labeled anti-rabbit specific 
antibody for 1h at room temperature. Blots were washed three times for 10 min with 
TBST and once with TBS and immunodetected using the Odyssey Infrared Imaging 
System (LI-COR® Biosciences, US). 
For loading control the bottom part of the membranes were incubated with Ponceau S. 
solution for 15 min at room temperature with slow agitation. The membranes were 
washed with distilled water until the protein bands were well defined and analyzed 
using the densitometer GS-800. To remove the staining, the membranes were washed 
with TBST 1X. The bottom part of the membranes was also blocked with 3% BSA in 
TBST-1X for 30 min and immunoblotted with mouse anti-β-tubulin (1:2000) for 1h at 
room temperature. Pixel intensity was quantified using Quantity One ® software. The 
intensity from an empty lane within each membrane was subtracted from all signals 
and all data was normalized to the Ponceau S. control.  
 
2.11. Bioinformatic analysis  
The data obtained by mass spectrometry was subjected to an extensive bioinformatic 
analysis. For the identification of testis/sperm enriched/specific proteins, cellular and 
subcellular localization proteins were searched against Human Protein Atlas (HPA), a 
tissue expression database. The criteria used in the database were set for a maximum 
stringency to identify the tissue-specific protein with a high confidence level. The 
Uniprot database was used to classify the proteins according their molecular function 
and biological process associated. Proteins associated with defects in male fertility or a 
functional/morphological defect in the male reproductive system were obtained from 
three databases: Diseases (http://diseases.jensenlab.org/Search), DisGeNET 
(http://www.disgenet.org/web/DisGeNET/menu;jsessionid=1q3ipxj2id1gbp3r47hkto884) 
and MGI (http://www.informatics.jax.org/). 
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3.  Results 
3.1. Peptides translocate into bovine spermatozoa at different 
rates  
Quantitative analysis of the uptake efficacies in bovine spermatozoa demonstrated that 
the peptides tested have different translocation rates (Supplementary Table 4). AKAP4-
BM internalized very efficiently, having the highest intracellular translocation efficacy of 
the three peptides tested, while AKAP4-BM M internalized less efficiently resulting in 
reduced fluorescent signal (Figure 7).  
 
Figure 7 - Quantitative analysis of peptide translocation into bovine spermatozoa. (A) Temporal-dependent 
intracellular uptake of TAMRA-labeled peptides into bovine spermatozoa. Bovine spermatozoa were 
incubated with TAMRA-labeled CPP (5 µM) at 37ºC for the times indicated. (B) Bovine spermatozoa were 
incubated with 5 µM, 7,5 µM and 10 µM of TAMRA-labeled peptides for 15 min at 37ºC. The experiments 
were performed in triplicated in three different bulls. Data are expressed as mean fluorescence ± s.e.m. 
 
At time zero, corresponding to the addition of the peptides to spermatozoa and 
immediate washing to remove the peptide containing solution, some peptide already 
entry in the sperm cells, revealing that peptides rapidly translocate into bovine 
spermatozoa. The amount of AKAP4-BM M peptide entering cells does not increase 
with time while AKAP4-BM and PPP1CC2-CT peptides uptake increased with time 
(Figure 7, A). However, it was observed that at 30 min of incubation with PPP1CC2-CT 
peptide the amount of peptide inside the sperm cells was less than at 15 min and 1h. 
This unexpected result can be explained by methodological errors.  
Incubations with different concentrations of the competitive peptides were tested at 15 
min in bovine spermatozoa and the intracellular translocation was evaluated (Figure 7, 
B and Supplementary Table 5). Exposure of bovine spermatozoa to increasing 
concentrations of AKAP4-BM peptide was followed by increasing intracellular 
translocation of the peptide. Similar results were found for PPP1CC2-CT and AKAP4-
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BM M peptides, however, with 7,5 µM of the AKAP4-BM M peptide the intracellular 
quantity of the peptide starts to stabilize. 
 
3.2.  Impact of the peptides on sperm motility  
Bovine spermatozoa were exposed to different extracellular peptide concentration (5 
µM and 10 µM) and motility parameters were accessed at 15 minutes (Supplementary 
Table 6 to Supplementary Table 8) using the Sperm Class Analyzer CASA System 
(Microptic S L, Barcelona, Spain) with SCA® v5.4 software (Figure 8). Negative 
controls were performed in the absence of peptides.  
 
 
Figure 8 – Example of the assessment of motility using the Sperm Class Analyzer CASA System 
(Microptic S L, Barcelona, Spain) with SCA® v5.4 software. At least 700 sperm cells per measurement 
were evaluated. Negative control without the peptides was performed (A). Samples treated with 5 µM of 
PPP1CC2-CT peptide showed more immotile spermatozoa (B) when compared to negative control. When 
compared with mutated AKAP4-BM peptide (AKAP4-BM M) (C) and with negative control (A), sperm cells 
treated with AKAP4-BM peptide (D) also showed reduced motility. Images are representative from three 
independent experiments. Red, fast progressive motile spermatozoa; Green, slow progressive motile 
spermatozoa; blue, non-progressive spermatozoa; yellow, immotile spermatozoa.   
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3.2.1. PPP1CC2-CT peptide 
After exposure of bovine spermatozoa to 5 µM of PPP1CC2-CT, a significantly 
reduction in fast (from 29,5±7,8% to 14,5±6,9%) and slow progressive motility (from 
9,9±4,4% to 5,9±2,2%) was observed comparing with negative control. Incubation of 
bovine spermatozoa with 10 µM of the same peptide induced significant reduction in 
fast progressive motility (from 29,5±7,8% to 15,0±7,8%) but not in slow progressive 
motility. On the other hand, immotile spermatozoa increased with both 5 µM (from 
37,3±9,6% to 58,1±9,3%) and 10 µM (from 37,3±9,6% to 50,5±13,3%) PPP1CC2-CT. 
No significant alterations were observed in non-progressive motility (Figure 9).  
The concentrations tested (5 µM and 10 µM) had similar results for all the parameters, 
except for slow progressive motility, suggesting that there was no concentration-
dependent effect of the PPP1CC2-CT peptide.  
 
Figure 9 - Impact of the treatment with PPP1CC2-CT peptide in bovine spermatozoa motility parameters: 
(A) fast progressive motility; (B) slow progressive motility; (C) non-progressive motility; (D) immotile 
spermatozoa. Graph bars represent the mean values of three independent experiments performed in 
triplicate. Error bars 95% CI. Statistically significant findings are indicated with a (*). *P<0,05. 
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3.2.2. AKAP4-BM peptide 
Exposure of bovine spermatozoa to 5 µM of AKAP4-BM peptide results in a decrease 
in fast progressive motility (from 29,5±7,8% in the negative control to 10,0±7,7%). 
Incubation with 10 µM also induced a decrease in fast progressive motility (from 
29,5±7,8% in the negative control to 7,7,0±5,7% in the treatment) and additionally, a 
decrease in slow progressive motility (from 9,9±4,4% in the negative control to 
8,8±3,7% in the treatment). In contrast, immotile spermatozoa increased with both 5 
µM (from 37,3±9,6% in the negative control to 56,1±8,3% in the treatment) and 10 µM 
(from 37,3±9,6% in the negative control to 62,0±13,1% in the treatment) AKAP-BM. 
Application of the mutated AKAP4-BM peptide did not lead to significant alterations in 
motility parameters (compared with negative control), except for fast progressive 
motility, that significantly decrease when spermatozoa were treated with 5µM of 
AKAP4-BM M  (from 29,5±7,8% to 21,5±7,1%) (Figure 10).  
 
Figure 10 - Impact of the treatment with AKAP4-BM peptide in bovine spermatozoa motility parameters: 
(A) fast progressive motility; (B) slow progressive motility; (C) non-progressive motility; (D) immotile 
spermatozoa. Graph bars represent the mean values of three independent experiments performed in 
triplicate. Error bars 95% CI. Statistically significant findings are indicated with a (*). *P<0,05. 
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3.3.  AKAP4-BM peptide disruptive potential on the AKAP4-
PPP1CC2 interaction 
 
3.3.1. PPP1CC2 and AKAP4 interact in spermatozoa  
To demonstrate the interaction of PPP1CC2 and AKAP4 in human spermatozoa we 
performed a co-immunoprecipitation using and isoform-specific anti-PPP1CC2 
antibody from normozoospermic human ejaculated sperm samples followed by 
immunoblotting. Endogenous PPP1CC2 was showed to co-immunoprecipitate with 
endogenous AKAP4 in normozoospermic human spermatozoa by Western blot (Figure 
11, lane 1), as previously reported [148]. However, the signal was weak. This was 
expected since AKAP4 is present in the insoluble fraction of the spermatozoa and is 
very resistant to extraction. 
 
Figure 11 – PPP1CC2 and AKAP4 interact in human spermatozoa revealed by co-immunoprecipitation, 
using an isoform-specific anti-PPP1CC2 antibody. Human sperm soluble extracts were co-
immunoprecipitated with anti-PPP1CC2 antibody and immunoblotted with mouse anti-AKAP4 antibody. 
Sperm soluble and insoluble extracts corresponding to 4 x 106 cells were also loaded. Co-IP, co-
immunoprecipitation; IB, immunoblot. Note that mouse anti-AKAP4 antibody has a reported unspecific 
band (*).   
 
3.3.2.  AKAP4-BM peptide disrupts PPP1CC2 and AKAP4 interaction 
PPP1CC2 inhibition is required for sperm motility and it is thought that AKAP4 is 
required for that inhibition. To determine if the effect of the AKAP4-BM peptide in 
sperm motility is due to AKAP4-PPP1CC2 interaction interference, we perform 
competition assays in bovine and human spermatozoa using 50µM and 10µM of the 
peptide. The AKAP4-BM peptide mimics the interaction interface between PPP1CC2 
and AKAP4 based on the RVxF motif, one of the best known PPP1C binding motifs. 
After incubation with the peptides a co-immunoprecipitation of PPP1CC2 was 
performed and the extracts were run in a 10% SDS-PAGE gel. The results revealed no 
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differences in the amount of AKAP4 bounded to PPP1CC2 in samples treated with the 
competition peptide (Figure 12).  
 
Figure 12 – Competition assay using 10µM and 50µM of AKAP4-BM peptide in human spermatozoa. 
Human sperm soluble extracts were co-immunoprecipitated with anti-PPP1CC2 antibody and 
immunoblotted with rabbit anti-AKAP4 antibody. No differences in the amount of AKAP4 bounded to 
PPP1CC2 were observed in the samples treated with the competition peptides when compared with 
negative control and with mutated AKAP4-BM peptide.  
Due to these results and to further explore this interaction interference, the levels of 
PPP1CC2 that interact with AKAP4 in HeLa cells transfected with pCMV6-AC-GFP-
AKAP4 in the presence of the peptides were determined by blot overlay (Figure 13). All 
the membranes were overlaid with PPP1CC2 purified protein and the corresponding 
peptide (AKAP4-BM or AKAP4-BM M) or inhibitor (I2). The control corresponds to the 
membrane overlaid only with PPP1CC2 purified protein, to establish the amount of 
PPP1CC2 that normally binds to AKAP4 (Figure 13, C). The results showed that in 
Hela cells extracts overlaid with AKAP4-BM peptide the amount of PPP1CC2 that 
binds to endogenous AKAP4 is lower (Figure 13, A), compared with control and with 
AKAP4-BM M peptide (Figure 13, B). These results suggest that AKAP4-BM peptide 
binds to PPP1CC2 purified protein, decreasing the amount of PPP1CC2 available for 
the interaction with endogenous AKAP4. The levels of PPP1CC2 protein bounded to 
AKAP4 were very similar between membranes overlaid with AKAP4-BM peptide and 
with I2 (Figure 13, D), an inhibitor of PPP1CC2, as expected. Ponceau S. was used as 
loading control (Supplementary Figure 1). 
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Figure 13 - Disruption of PPP1CC2/AKAP4 interaction by AKAP4-BM peptide. HeLa cells extracts were 
run on SDS-PAGE gels. Prior to immunoblot with anti-PPP1CC2 antibody the membrane was overlaid with 
(A) purified PPP1CC2 and AKAP4-BM peptide; (B) purified PPP1CC2 and AKAP4-BM M peptide; (C) 
purified PPP1CC2 and (D) purified PPP1CC2 and I2. Pixel intensity was quantified using Quantity One ® 
software and Ponceau S. staining was used as loading control (Supplementary Figure 1). The amount of 
PPP1CC2 that binds to AKAP4 in the presence of the AKAP4-BM peptide is reduced when compared with 
AKAP4-BM M peptide and with negative control (PPP1CC2 only).  
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3.4. Characterization of the PPP1CC2-CT peptide interactome: 
Identification of proteins that specifically interact with the 22-
amino acid C-terminus of the human PPP1CC2 
 
To identify PPP1CC2-specific interactors, human spermatozoa were incubated with 
biotinylated PPP1CC2-CT peptide for 15 min and a co-immunoprecipitation of the 
peptide was performed followed by intensity-based label-free quantitative (LFQ) LC-
MS/MS analysis. Peptide-spectrum matches and protein identifications were filtered 
using a “target-decoy approach”, a powerful strategy to deliver false positive 
estimations that can be applied to nearly any MS/MS workflow [149,150], at a false 
discovery rate (FDR) of 1%, providing confident identification of proteins (FDR < 1%). 
Two peptides that matched with PPP1CC2-CT peptide were identified (Table 4) and 
PPP1CC is ranked as 27th most abundant protein which indicates good bait recovery 
after pull down.  
 
Table 4- PPP1CC2-CT peptides identified by mass spectrometry after co-immunoprecipitation of 
biotinylated PPP1CC2-CT in human spermatozoa samples. 
Sequence Protein Start position End position Score 
KPNATRPVTPPR P36873 303 314 99,5 
PNATRPVTPPR P36873 304 314 45,829 
 
Mass spectrometry data also showed 73 proteins upregulated in samples incubated 
with the peptide when compared with the negative controls. Interactors were identified 
using a student’s t-test comparing the LFQ intensities of all proteins identified in 
replicates of CT with the LFQ intensities of all proteins identified in the control. Proteins 
were classified as interactors according to their position in the volcano plot (Figure 14). 
When log2(CT/NC) and -log(p-value) were plotted against each other in a volcano plot 
the unspecific background binders appears around zero. The interactors appear on the 
right side of the volcano plot and the higher the difference between the group means 
and the p value the more the interactors move to the top right corner of the plot, which 
is the area of highest confidence for a true interaction. Among these 73 proteins, 23 
proteins were classified as contaminants and consequently excluded (e.g. 22 ribosomal 
proteins and one extracellular matrix glycoprotein). In fact, most ribosomal proteins 
were also detected in the negative control samples and previous findings indicate that 
these proteins have high affinity to the magnetic beads [151]. Only proteins that were 
quantified in at least 3 replicates of one of both conditions were considered. 
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Figure 14 - Identification of PPP1CC2-CT interactors. Proteins are classified as interactors according to 
their position in the volcano plot. The enriched interactors appear on the right side of the plot, in red.  
Thus, we identified 50 proteins that interact with the 22 amino acids C-terminus of 
human PPP1CC2 (Supplementary Table 9). From those, ten are testis 
specific/enriched proteins (YBX2, H1FNT, CSNK1A1L, TBL2, PRSS37, HIST1H2BA, 
ZPBP2, ACR, SERPINA5 and KLHL10). The majority of the proteins identified as 
PPP1CC2-CT interactors are localized intracellularly (80%) or are secreted (36%). A 
minority is associated to the membrane (10%) (Table 5). 
Analysis of human testicular, epididymal and sperm proteomes allowed the 
classification of (i) YBX2 as sperm-located epididymal protein also detected in the 
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sperm-milieu; (ii) TBL2, GPX4 and KLHL10 as sperm-milieu epididymal proteins; (iii) 
AARSD1 and ECH1 as testicular protein; (iv) H1FNT and CRISPLD2 as a sperm-
located testicular protein also detected in sperm milieu; and (v) CLU as a sperm 
located testicular/epididymal protein also detected in sperm milieu (Table 5). According 
to the information collected in the Disease and DisGeNET databases, eleven proteins 
(YBX2, H1FNT, SEMG1, PRSS37, HIST1H2BA, PSME4, SEMG2, ACR, GPX4, 
PPP1CC and KLHL10) are associated with male infertility phenotypes, more 
specifically with azoospermia (YBX2, PPP1CC, PA2G4 and KLHL10), oligozoospermia 
(YBX2, PPP1CC and KLHL10), asthenozoospermia (KLHL10), abnormal 
spermatogenesis (YBX2) and varicocele (SEMG2). Besides that, twelve PPP1CC2-CT 
putative interactors are connected to reproductive phenotypes in gene knockout 
models (YBX2, H1FNT, SEMG1, PRSS37, ZPBP2, PSME4, ACR, SERPINA5, GPX4, 
YBX3, PPP1CC and KLHL10). 
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Table 5 – Characterization of the 50 PPP1CC2-CT peptide interactors identified by LC-MS/MS analysis. Loc, localization; I, intracellular; S, secreted; M, membrane. 
Uniprot 
ID Protein name Gene name 
Tissue 
expression Loc Molecular Function 
Human proteomes 
[152] 
Identified in spermatozoa 
under specific conditions 
Q00577 Transcriptional activator protein Pur-alpha PURA Mixed I Activator, DNA-binding   
P02788 Lactotransferrin LTF 
Tissue 
enhanced (bone 
marrow, cervix, 
uterine) 
I, S 
Antibiotic, Antimicrobial, 
DNA-binding, Heparin-
binding, Hydrolase, 
Protease, Serine protease 
 
Decrease ROS level 
(down; up) [153]; Diabetes 
type I and II (up) [154]; 
DNA fragmentation (up) 
[155]; Obesity (up) [154]; 
Poor blastocyst 
development (down) [156] 
Q9Y2T7 Y-box-binding protein 2 YBX2 Tissue enriched (testis) I DNA-binding, RNA-binding 
Sperm-located 
epididymal protein also 
detected in sperm-
milieu 
 
Q75WM6 Testis-specific H1 histone H1FNT Tissue enriched (testis) I 
Developmental protein,  
DNA-binding 
Sperm-located 
testicular protein also 
detected in sperm-
milieu 
Non-progressive motility 
(up)[157]; 
P11940 Polyadenylate-binding protein 1 PABPC1 Expressed in all I RNA-binding   
P43155 Carnitine O-acetyltransferase CRAT Expressed in all I Acyltransferase, Transferase  
Poor blastocyst 
development (down) [156] 
P37108 Signal recognition particle 14 kDa protein SRP14 Expressed in all I; S 
Ribonucleoprotein,  
RNA-binding   
Q6NUI6 Chondroadherin-like protein CHADL 
Tissue 
enhanced 
(cerebral cortex) 
I; S    
O75569 
Interferon-inducible double-stranded 
RNA-dependent protein kinase activator 
A 
PRKRA Expressed in all I RNA-binding   
P48729 Casein kinase I isoform alpha CSNK1A1 Expressed in all I; M 
Kinase,  
Serine/threonine-protein 
kinase, Transferase    
Q8N752 Casein kinase I isoform alpha-like CSNK1A1L Tissue enriched (testis) I 
Kinase,  
Serine/threonine-protein 
kinase, Transferase 
  
Q7L2E3 Putative ATP-dependent RNA helicase DHX30 Expressed in all I; S Helicase, Hydrolase,    
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Uniprot 
ID Protein name Gene name 
Tissue 
expression Loc Molecular Function 
Human proteomes 
[152] 
Identified in spermatozoa 
under specific conditions 
DHX30 RNA-binding 
Q9Y4P3 Transducin beta-like protein 2 TBL2 Tissue enriched (testis) I; S  
Sperm-milieu 
epididymal protein  
P04279 Semenogelin-1 SEMG1 Tissue enriched (seminal vesicle) S   
Decrease ROS level (up; 
down) [153]; Diabetes type 
I (up [154]; down [158]); 
Diabetes type II (up; down) 
[154]; DNA fragmentation 
(up) [155]; Idiopathic 
Infertility (up) [159,160]; 
IVF failure (up) [159]; 
Obesity (up) [154]; 
Q8N0Z8 tRNA pseudouridine synthase-like 1 PUSL1 Expressed in all I Isomerase   
A4D1T9 Probable inactive serine protease 37 PRSS37 Tissue enriched (testis) S    
Q96A08 Histone H2B type 1-A HIST1H2BA Tissue enriched (testis) I DNA-binding  IVF failure (up) [159] 
Q9BTE6 Alanyl-tRNA editing protein Aarsd1 AARSD1 Expressed in all I  Testicular protein  
Q9Y2C4 Nuclease EXOG, mitochondrial EXOG Mixed I; S Endonuclease,  Hydrolase, Nuclease   
O95782 AP-2 complex subunit alpha-1 AP2A1 Expressed in all I    
O94973 AP-2 complex subunit alpha-2 AP2A2 Mixed I    
Q07021 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1QBP Expressed in all I    
Q6X784 Zona pellucida-binding protein 2 ZPBP2 Tissue enriched (testis) S   
DNA fragmentation (up) 
[155] 
Q14997 Proteasome activator complex subunit 4 PSME4 Expressed in all I Developmental protein  
Non-progressive motility 
(up) [157] 
Q9UHI8 A disintegrin and metalloproteinase with thrombospondin motifs 1 ADAMTS1 
Tissue 
enhanced 
(ovary) 
I; M; 
S 
Heparin-
binding, Hydrolase, Metallo
protease, Protease   
P61626 Lysozyme C LYZ Expressed in all S 
Antimicrobial,  
Bacteriolytic enzyme,  
Glycosidase, Hydrolase   
Q9H0B8 Cysteine-rich secretory protein LCCL CRISPLD2 Expressed in all I; S  Sperm-located  
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Uniprot 
ID Protein name Gene name 
Tissue 
expression Loc Molecular Function 
Human proteomes 
[152] 
Identified in spermatozoa 
under specific conditions 
domain-containing 2 testicular protein also 
detected in sperm-
milieu 
Q02383 Semenogelin-2 SEMG2 Tissue enriched (seminal vesicle) S   
Decrease ROS level 
(down)[153]; Idiopathic 
Infertility (up) [160]; Obesity 
(down) [158] 
P10323 Acrosin ACR Tissue enriched (testis) S 
Hydrolase, Protease,  
Serine protease  
DNA fragmentation (up) 
[155]; Idiopathic Infertility 
(down) [159] 
Q8TDZ2 Protein-methionine sulfoxide oxidase MICAL1 MICAL1 Mixed I 
Actin-binding,  
Monooxygenase, Oxidored
uctase   
Q92820 Gamma-glutamyl hydrolase GGH 
Tissue 
enhanced 
(kidney) 
S Hydrolase  
Diabetes type I and II 
(down) [154]; Non-
progressive motility (down) 
[157] 
P61163 Alpha-centractin ACTR1A Expressed in all I    
P05154 Plasma serine protease inhibitor SERPINA5 
Tissue 
enhanced 
(testis, adrenal 
gland, liver) 
S 
Heparin-binding, Protease 
inhibitor, Serine protease 
inhibitor   
Q8IVS2 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial MCAT Expressed in all I Transferase   
Q13618 Cullin-3 CUL3 Expressed in all I    
P36969 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial GPX4 Expressed in all I; S 
Developmental protein,  
Oxidoreductase,  
Peroxidase 
Sperm-milieu 
epididymal protein 
Asthenozoospermia 
(up)[161]; Idiopathic 
Infertility (down) [160]; 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial DECR1 Expressed in all I Oxidoreductase   
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial ECH1 Expressed in all I Isomerase Testicular protein  
P10909 Clusterin CLU Expressed in all I; S Chaperone 
Sperm-located 
testicular/epididymal 
protein also detected in 
sperm-milieu 
Diabetes type I and II (up) 
[154]; DNA fragmentation 
(up) [155]; Increased age 
(up) [162]; IVF failure (up) 
[159]; Idiopathic Infertility 
(up) [160]; Obesity (up) 
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Uniprot 
ID Protein name Gene name 
Tissue 
expression Loc Molecular Function 
Human proteomes 
[152] 
Identified in spermatozoa 
under specific conditions 
[154]; Poor blastocyst 
development (up) [156]; 
Round-headed 
spermatozoa (up) [163]; 
O75390 Citrate synthase, mitochondrial CS Expressed in all I; M Transferase  
DNA fragmentation (up) 
[155] 
P36957 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial 
DLST Expressed in all I Acyltransferase,  Transferase  
Asthenozoospermia (down) 
[157] 
P67809 Nuclease-sensitive element-binding protein 1 
 
YBX1 Expressed in all I 
Activator, DNA-
binding, Mitogen,  
Repressor, RNA-binding, 
DNA-binding, Repressor 
  
P16989 Y-box-binding protein 3 YBX3 Expressed in all I 
Activator, DNA-
binding, Mitogen,  
Repressor, RNA-binding, 
DNA-binding, Repressor 
  
P36873 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit PPP1CC Expressed in all I 
Hydrolase, Protein 
phosphatase   
Q9Y285 Phenylalanine--tRNA ligase alpha subunit FARSA Expressed in all I 
Aminoacyl-tRNA 
synthetase, Ligase   
Q9UGP8 Translocation protein SEC63 homolog SEC63 Expressed in all M Chaperone   
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 Expressed in all I 
Repressor,  
Ribonucleoprotein,  
RNA-binding   
Q6JEL2 Kelch-like protein 10 KLHL10 Tissue enriched (testis) I  
Sperm-milieu 
epididymal protein  
Q92523 Carnitine O-palmitoyltransferase 1, muscle isoform CPT1B Expressed in all M 
Acyltransferase,  
Transferase   
Q04837 Single-stranded DNA-binding protein, mitochondrial SSBP1 Expressed in all I DNA-binding  
Non-progressive motility 
(up) [157] 
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To confirm the interaction between the PPP1CC2-CT peptide and a protein identified in 
the LC-MS/MS analysis, a fraction of the co-immunoprecipitation with the biotinylated 
PPP1CC2-CT peptide was run on a SDS-PAGE gel and immunoblotted with rabbit 
anti-GPX4 antibody. The results showed that PPP1CC2-CT co-immunoprecipitates 
with endogenous GPX4 in normozoospermic human spermatozoa (Figure 15, lane 1). 
 
Figure 15 - GPX4 interacts with C-terminus of PPP1CC2 protein. Co-immunoprecipitation of PPP1CC2-CT 
from ejaculated normozoospermic human sperm sample followed by immunoblot with ant-GPX4 antibody 
showed PPP1CC2-CT/GPX4 interaction. Sperm soluble and insoluble extracts were also loaded. Co-IP, 
co-immunoprecipitation; IB, immunoblot. 
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4. Discussion 
 
In the past decades, PPIs have emerged as promising drug targets. Several 
approaches were used to modulate these interactions, one of them involves the use of 
CPPs as intracellular delivery vectors. This short peptide sequences, usually with less 
than 30 amino acids in length often with positive charge, are able to cross through the 
cellular membrane and deliver different types of cargo [96,102]. This strategy allows 
the delivery of drugs that are usually unable to cross an intact lipid barrier. In terms of 
clinical applications, CPPs can be used to deliver a wide range of therapeutic moieties, 
including small molecules, liposomes, nanoparticles and biopharmaceuticals including 
oligonucleotides, peptides and proteins [94,97]. The CPP used in this study to deliver 
the peptides sequences was penetratin, an inert CPP that efficiently translocate into 
spermatozoa flagellum [138]. The intracellular accumulation of the TAMRA-labeled 
peptides was quantified in bovine spermatozoa. AKAP4-BM and PPP1CC2-CT 
peptides internalized more efficiently than AKAP4-BM M in bovine spermatozoa (Figure 
7, A). Those results were in accordance with the preliminary data obtained by 
fluorescent microscopy and quantitative translocation analyses of the same TAMRA-
labeled peptide at 1h in bovine spermatozoa [164]. Jones at al. previously demonstrate 
that CPPs enter very fast in the mammalian spermatozoa, with a half-time between 1 
and 3 min, dependent on the CPP [138]. This study showed that only a few minutes 
were necessary to the peptides enter the sperm cell, indicate that CPP readily 
translocate into bovine spermatozoa. Higher concentrations reflect a higher cellular 
uptake but lower concentrations should be tested to achieve approximately the same 
intracellular uptake of the peptides. Plasma membrane integrity of spermatozoa could 
be affected by storage in liquid nitrogen [147,165], increasing the permeability of sperm 
cells which can affect the uptake results. Further studies using fresh bovine samples 
and performing a vitality analysis prior to the uptake test are necessary to confirm the 
results. 
Exposure of bovine and human spermatozoa to the competition peptides for 1h and 2h 
induced significant alterations in motility parameters, without altering cell viability [164]. 
The present results showed that exposure of bovine spermatozoa to the PPI disruptor 
peptide sequences induced significant alteration in motility parameters as early as 15 
min (Figure 9 and Figure 10).  
This study demonstrated that AKAP4-BM, a synthetic peptide that contains a variant of 
the RVxF motif, was successfully delivered to spermatozoa and led to a significantly 
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alteration in sperm motility parameters. Upon treatment of bovine spermatozoa with the 
AKAP4-BM peptide, the percentage of fast progressive motility declined (Figure 10, A). 
Slow progressive motility also decreased upon exposure to 5 µM of AKAP4-BM 
peptide, when compared with negative control, and upon exposure to 10 µM of AKAP4-
BM peptide, when compared with the treatment with mutated AKAP4-BM peptide. In 
turn, the percentage of immotile spermatozoa increased significantly (Figure 10, D). 
Exposure to the mutated AKAP4-BM peptide did not lead to significant differences in 
motility parameters, when compared to negative control, except for 5 µM of AKAP4-BM 
M that induced significant decrease in fast progressive motility. Several findings 
suggest that AKAP/PRKA/PPP1 complex is essential for sperm motility regulation. 
AKAP4, the major protein of the fibrous sheath of the flagellum, is one of the three 
AKAPs that have been related to PPP1CC2 [85]. The targeted disruption of the Akap4 
gene in mice compromise sperm flagellum morphology through the lack of fibrous 
sheath of the principal piece, resulting in male infertility. [21]. In addition, Akap4 gene 
knockout in mice change PPP1CC2 activity and phosphorylation, as demonstrated by 
Huang and colleagues [89]. Recently, Silva et al. (2017) [148] reported for the first time 
that AKAP4 interacts with PPP1CC2 in ejaculated human spermatozoa, which was 
also confirmed in this study. Since PPP1CC2 inhibition is required for sperm motility 
and AKAP4 seems to be involved in that inhibition, we hypothesized that the loss of 
sperm motility resulting from the AKAP4-BM peptide treatment was due to PPP1CC2-
AKAP4 interaction disruption. To test that hypothesis, competition assays using 
different concentrations of the AKAP4-BM peptide were performed in vitro. The results 
demonstrated that upon exposure to the competition peptide, the amount of PPP1CC2 
that binds to AKAP4 was reduced, which support the theory that the peptide interfere 
with PPP1CC2-AKAP4 interaction (Figure 13). 
Further studies are needed to determine the alteration on PPP1CC2 activity and 
phosphorylation status, upon exposure to the AKAP4-BM peptide, by using 
phosphatase assays and of global protein serine/threonine phosphorylation status. The 
assessment of PPP1CC2 activity and global phosphorylation levels might help to 
understand the impact of peptides at the cellular level that possibly affect the 
spermatozoa motility. The same experiments should be performed in human 
spermatozoa to confirm and clarify the impact of peptides in spermatozoa.  
Upon treatment with the PPP1CC2-CT peptide the percentage of fast progressive 
motility significantly decreased with both concentrations tested (Figure 9, A) and the 
percentage of immotile spermatozoa significantly increased (Figure 9, D), similarly to 
what was already showed for 10 µM and 20 µM of the same peptide at 1h and 2h 
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[164]. Regarding slow progressive motility, significant alterations were only observed 
upon treatment with 5 µM of PPP1CC2 peptide. The effect observed in sperm motility 
seems to be independent of peptide concentration, as previously demonstrated. These 
results were in accordance with what was described for these peptides, showing that 
peptides rapidly entry in the sperm cells and induced significant alterations in sperm 
motility as early as 15 min of incubation. The same experiments should be performed 
in human spermatozoa to confirm and clarify the impact of peptides in spermatozoa. 
Further studies are necessary to investigate if the impact of the peptides in sperm 
motility is reversible, when the peptide is removed.    
PPP1CC2-CT peptide mimics the unique 22 amino acid C-terminus of PPP1CC2 and 
probably compete with isoform-specific interactors of this phosphatase, affecting its 
action and, thus, sperm motility (Figure 16, A). Endophilin B1t, a testis enriched isoform 
of the somatic endophilin B1a, and the spermatogenic zip protein (Spz1) [67,68] are 
two isoform-specific interactors previously identified in testes. In order to identify other 
PPP1CC2-specific interactors, the interactome of PPP1CC2-CT peptide was 
performed in human spermatozoa. Of the 50 PPP1CC2-CT interactors identified by LC-
MS/MS analysis, 10 were identified as testes specific/enriched proteins. Eight proteins 
were associated with abnormal sperm motility phenotypes (H1FNT, SEMG-1, PSME4, 
GGH, SERPINA5, mGPx4, DLST and SSBP1).  
One of the interactors identified was GPx4 – identified for the first time in pig liver [166] 
and involved in several biological functions, including sperm maturation [167,168]. 
Despite their expression in most mammalian tissues, larger amounts are present in 
testes [169] and spermatozoa. In sperm cells two isoforms were described – sperm 
nucelar GPx4 (snGPx4) and midpiece GPx4 (mGPx4). In mature spermatozoa, mGPx4 
exists as an enzymatically inactive insoluble protein, constituting 50 percent of the 
capsule material that surround the mitochondrial sheath where is cross-linked with 
other capsule proteins  [167]. Thus, mGPx4 constitute the major structural constituent 
of mitochondrial capsules that surround mitochondria in the midpiece of mature 
spermatozoa. GPX4 was identified in asthenozoospermic male [161] and GPx4 gene 
knockout mice was infertile due to abnormal sperm motility, morphology and physiology 
[168,170,171]. The infertility phenotype observed in mice lacking GPx4 results from 
midpiece structural defects and not from loss of enzymatic activity [170,171]. In the 
present study was showed by LC-MS/MS and by Western Blot that GPx4 interacts with 
the 22 amino acids C-terminus of PPP1CC2, constituting a putative isoform-specific 
interactor. Additionally, both PPP1CC2 and GPx4 activity deregulation was previously 
associated with sperm motility arrest and both proteins are present in sperm midpiece, 
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supporting the hypothesis that these proteins might have a common role in 
spermatozoa motility. However, further studies are needed to explore PPP1CC2-GPx4 
interaction and clarify the role of this complex on sperm motility. 
Disruption of motility-related PPP1CC2-PIP interactions potentially generate active 
PPP1CC2 that dephosphorylate a subset of substrates and prevent motility acquisition. 
The identification of novel PPP1CC2-specific interactors represents a good target for 
new contraceptive methods, capable of modulate PPP1CC2 activity, an isoform only 
present in testes/spermatozoa, by targeting/disrupting these interactions. 
 
Figure 16 - Disruption of PPP1CC2- specific PIP and PPP1CC2/AKAP4 complex using cell-penetrating 
peptides as drug intracellular delivery system. (A) In spermatozoa, PPP1CC2 usually interacts with PIP. In 
the presence of PPP1CC2-CT peptide, PIP that specifically bind to the 22-amino acid C-terminus of 
PPP1CC2, bind to the peptide instead of bind to endogenous protein, resulting in activation of PPP1CC2 
and, thus, arrest of sperm motility. (B) AKAP4-PPP1CC2 complex is essential for regulation of sperm 
motility. When spermatozoa were treated with AKAP4-BM mutant peptide, the peptide sequence interacts 
with endogenous PPP1CC2 through the RVxF motif, competing with endogenous AKAP4. The disruption 
of AKAP4/PPP1CC2 interaction results in active PPP1CC2 and, consequently, immotile spermatozoa.   
PPP1 BM, PPP1 binding motif. 
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5.  Conclusions and future perspectives 
 
5.1.  Conclusions 
The main objective of this thesis was to modulate protein complexes and, 
consequently, sperm motility using cell-penetrating peptides that specifically interact 
with non-hormonal targets selectively expressed in testis and sperm.  
To achieve this goal, PPP1CC2-specific interactions and PPP1CC2/AKAP4 complex 
were successfully modulated in spermatozoa using lower concentrations and 
incubation times of CPPs previously synthetized in the laboratory with known impact on 
sperm motility.  
A peptide sequence that mimics the interaction interface between PPP1CC2 and 
AKAP4 was successfully delivered to the spermatozoa with a significantly impact in 
sperm motility, as previously showed with higher concentrations and longer incubation 
times. Competition assays using the competition peptide allowed to confirm that the 
effect on sperm motility is due to PPP1CC2/AKAP4 interaction interference. 
A CPP was used to deliver a peptide sequence that mimics the unique 22 amino acid 
C-terminus of PPP1CC2 into spermatozoa, compromising isoform-specific interaction 
and, thus, affecting sperm motility, confirming the previously results obtained with 
higher concentrations at 1h and 2h of incubation. The same peptide was used to 
identify isoform-specific interactors, some of them associated with male infertility and 
abnormal sperm motility. In fact, despite some PPP1CC2-specific interactors were 
reported in testes, this is the first report of PPP1CC2 C-terminus interactome in 
spermatozoa. Fifty proteins were identified using LC-MS/MS analysis and one of them 
– GPx4 – was validated by Western Blot analysis. These proteins can constitute 
potential targets for new male contraceptives.  
Concluding, this work modulated protein complexes involved in spermatozoa motility in 
human and bovine spermatozoa and identify PPP1CC2 C-terminus-specific interactors 
that can be used as potential targets for new male contraceptive methods. 
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Figure 17 - Overview of the main goals and main conclusions of this thesis. (A) All peptide sequences 
tested were successfully delivered to the cell, with a significant impact on sperm motility at lower 
concentration and shorter incubation times than previously observed at our laboratory; (B) The AKAP4-BM 
peptide was demonstrated to disrupt the PPP1CC2-AKAP4 interaction; (C) Fifty putative interactors of 
PPP1CC2-CT were identified by LC-MS/MS analysis. 
 
5.2.  Future perspectives  
This study validated the previous results from the laboratory that designed peptides 
can efficiently modulate spermatozoa complexes and consequently modulate sperm 
motility. Future work should focus upon the identification of novel sperm-specific 
targets and design of peptide sequences conjugated with CPP to modulate them. The 
most promising candidates will be validated in human sperm samples and detailed in 
vivo studies will be performed. In vivo studies should allow, for example, to access the 
capacity of these compounds to cross the blood-epididymis barrier. 
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Supplementary Data 
 
Supplementary Table 1 - Solutions used in the experiments. 
Quantitative uptake analysis 
1% Trypsin (wt/vol) For 10 ml of deionized water dissolve 0,1g of trypsin. Adjust pH to 7.5-8.5 with NaOH. 
0,1 M NaOH For 100 ml of deionized water dissolve 0,4g of NaOH. 
Co-immunoprecipitation 
1X RIPA + 0,1mM PMSF 
(lysis buffer) 
For a final volume of 1 ml add 100µl of 10X RIPA and 
1µl of PMSF 0,1M to 1799µl of deionized water. 
Trypsin digestion buffer 
For a final volume of 50 ml add 1 mL of 1M Tris-HCl 
pH 8.0 and 0,1 mL of 1M CaCl2 to 50 ml of deionized 
water. 
CaCl2 1M For a final volume of 50 ml dissolve 7,35g CaCl2 dihydrated in 50 ml of deionized water. 
Western Blot 
Running gel 10% (2 gels, 
1,5 mm thickness) 
ddH2O 
Tris 1.5M pH8.8 
Acrylamide 40% 
Bisacrylamide 2% 
SDS 10% 
APS 10% 
TEMED 
7,720 ml 
5,000 ml 
4,920 ml 
1,960 ml 
0,200 ml 
0,100 ml 
0,020 ml 
Running gel 15% (2 gels, 
1,5 mm thickness) 
ddH2O 
Tris 1.5M pH8.8 
Acrylamide 40% 
Bisacrylamide 2% 
SDS 10% 
APS 10% 
TEMED 
4,2800 ml 
5,000 ml 
7,360 ml 
2,960 ml 
0,200 ml 
0,100 ml 
0,020 ml 
Stacking gel 4% (2 gels, 1,5 
mm thickness) 
ddH2O 
Tris 0,5M pH6.8 
Acrylamide 40% 
Bisacrylamide 2% 
SDS 10% 
APS 10% 
TEMED 
4,736 ml 
2,000 ml 
0,784 ml 
0,320 ml 
0,080 ml 
0,040 ml 
0,008 ml 
Tris-HCl 1.5M pH 8.8 buffer 
For 1L dissolve 181,5g Tris in 800 mL deionized 
water. Adjust pH at 8.8 with HCl and make up to 1L 
with deionized water. 
Tris-HCl 0,5M pH 6.8 buffer 
For 1L dissolve 60g Tris in 800 mL deionized water. 
Adjust pH at 6.8 with HCl and make up to 1L with 
deionized water. 
10% APS (ammonium 
persulfate) For 10 ml of deionized water add 1g of APS. 
10% SDS (sodium 
dodecilsulfate) For 500 mL of deionized water dissolve 50g of SDS. 
4X Loading gel buffer For 10 ml add 44 ml glycerol, 250 µl Tris-HCl 0.5M pH 
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6.8 buffer, 0,8g SDS, 0,2 ml β-mercaptoethanol and 
3,3 ml deionized water. Add bromophenol blue (a 
small amount). Keep it at RT for short periods or at 
4ºC for longer periods. 
Tris-Gly 10X Stock For 1L dissolve 30,30g Tris (250mM) and 144,10g Gly (1,92 M) in 1L of deionized water. 
Running buffer 1X 
For 1L add 800 ml deionized water, 100 ml Tris-Gly 
10X and 10 ml 10%SDS. Make up to 1L with 
deionized water. 
Transfer buffer 1X For 1L add 100 ml Tris-Gly 10X to 700 ml of deionized water and 200 ml methanol. 
10X TBS Stock (Tris 
buffered saline) 
For 0,5 L dissolve 6,055g Tris in deionized water and 
adjust pH at 8.0. Add 43,8325 g NaCl and make up to 
500 ml with deionized water. 
1X TBST (TBS + Tween 20) For 1 L add 100 ml TBS 10X and 500 µl Tween-20 to 900 ml of deionized water. 
5% BSA in TBST 1X For 100 ml of solution dissolve 5 g of BSA in TBST 1X. 
Ponceau S. 
For 100 ml of Ponceau S. staining solution dissolve 
0,1 g of Ponceau S. in 5 ml of acid acetic and fill up to 
100 ml with deionized water. 
 
Supplementary Table 2 - Basic semen parameters of 6 random men providing semen 
samples for routine analysis. PM, progressive motility; NPM, non-progressive motility; IM, 
immotile spermatozoa; MP, midpiece; ERC, excess of residual cytoplasm. 
Volunteer Volume (ml) 
Concentration 
(x 106/ml) 
No. 
spermatozoa 
(x 106) 
Motility (%) Morphology (%) 
Total PM NPM I Normal Head MP Tail ERC 
1 2.4 84 201.6 55 44 11 45 10 88 48 42 1 
2 1.9 31 58.9 65 51 14 35 14 68 36 36 0 
3 2.8 71 198.8 61 41 20 39 5 87 55 46 0 
4 1.6 180 288 63 54 9 37 16 80 59 42 0 
5 3.8 68 258.4 55 46 9 45 6 70 58 44 0 
6 1.2 38 45.6 49 32 17 51 21 68 38 29 0 
 
Supplementary Table 3 - Standards for BCA assay 
Standards BSA (µl) 1% SDS (µl) Protein (µg) 
P0 - 25 0 
P1 0.5 24.5 1 
P2 1 24 2 
P3 2.5 22.5 5 
P4 5 20 10 
P5 10 15 20 
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Supplementary Table 4 - Temporal-dependent quantitative analysis of peptide 
translocation into bovine spermatozoa. Bovine spermatozoa were incubated with 5 µM 
TAMRA-labeled bioactive CPP for 15, 30 and 60 min at 37ºC. Data are expressed as 
fluorescence. Three independent experiments were performed in triplicate.  
 Experiment 1 Experiment 2 Experiment 3 
Condition 1 2 3 1 2 3 1 2 3 
0 min 
NC    4473 3039 2695 1641 87 229 
AKAP4-BM    24209 14724 19681 7598 6230 9061 
AKAP4-BM M    5163 5566 4852 1172 4762 1462 
PPP1CC2-CT    13331 11564 15691 3247 4165 2903 
15 min 
NC 181 156 167 114 101 125 40 51 57 
AKAP4-BM 20025 33081 33527 17050 14700 13737 6256 5380 6424 
AKAP4-BM M 6171 3637 4391 6471 4189 7037 4936 1902 2174 
PPP1CC2-CT 13432 14383 11398 13559 14787 18710 6921 7038 7465 
30 min 
NC 200 162 165 321 1406 1085 2034 1901 340 
AKAP4-BM 30473 20887 17951 19003 20275 24131 11892 12604 37253 
AKAP4-BM M 3630 3413 3599 6899 11953 6057 2946 2392 2077 
PPP1CC2-CT 8651 7973 8234 6523 9440 13418 7357 4463 3373 
60 min 
NC 189 205 166 1866 976 1032 2847 237 239 
AKAP4-BM 36461 33310 33785 39592 25402 37957 15764 12404 16529 
AKAP4-BM M 3817 3754 3445 14289 8803 10693 4099 6299 3843 
PPP1CC2-CT 9772 10919 8365 25027 26192 24467 7899 7853 10144 
 
 
Supplementary Table 5 – Concentration-dependent quantitative analysis of peptide 
translocation into bovine spermatozoa. Bovine spermatozoa were incubated with 5 µM, 
7,5 µM and 10 µM TAMRA-labeled bioactive CPP for min at 37ºC. Data are expressed as 
fluorescence. Three independent experiments were performed in triplicate. 
 Experiment 1 Experiment 2 Experiment 3 
Condition 1 2 3 1 2 3 1 2 3 
AKAP4 
0 228 259 262 114 101 125 40 51 57 
5 25457 17710 22705 17050 14700 13737 6256 5380 6424 
7,5 16823 44164 38758 21278 21033 19793 8613 10991 9520 
10 40506 37796 37053 25475 31087 27379 17791 13948 13422 
AKAP4-BM 
M 
0 228 259 262 114 101 125 40 51 57 
5 3254 2681 2677 6471 4189 7037 4936 1902 2174 
7,5 4756 5164 6224 5628 10703 13309 2252 3557 3324 
10 4051 5365 3803 11122 10930 8894 3313 3756 4155 
PPP1CC2-
CT 
0 228 259 262 114 101 125 40 51 57 
5 7575 6379 5289 13559 14787 18710 6921 7038 7465 
7,5 12655 13818 16268 8787 17967 11532 9213 9279 11705 
10 17259 15094 12270 24928 15877 22330 10502 8224 9806 
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Supplementary Table 6 – Descriptive analysis; Statistical measures: Mean and standard 
deviation (SD) associated with CPP treatments in bovine spermatozoa; NC, negative 
control; PM, progressive motility; NPM, non-progressive motility; IM, immotile 
spermatozoa. Data are expressed as mean of three independent experiments performed 
in triplicate. 
 
15 min 
PPP1CC2-CT AKAP4-BM AKAP4-BM M NC 
5 µM 10 µM 5 µM 10 µM 5 µM 10 µM 5 µM 10 µM 
PM fast (%) Mean 14,5 15,0 10,0 7,7 21,5 29,6 29,5 29,5 SD 6,9 7,8 4,3 5,7 7,1 15,8 7,8 7,8 
PM slow (%) Mean 5,9 8,3 7,1 8,8 8,8 10,3 9,9 9,9 SD 2,2 4,3 2,6 3,7 3,7 4,2 4,4 4,4 
NPM (%) Mean 21,4 26,2 26,8 24,4 25,5 21,0 23,3 23,3 SD 2,6 6,2 6,5 7,5 5,5 5,7 2,7 2,7 
IM (%) Mean 58,1 50,5 56,1 62,0 44,2 39,1 37,3 37,3 SD 9,3 13,3 8,3 13,1 12,3 16,1 9,6 9,6 
  
Supplementary Table 7 – Inferential statistics; Test for differences between means of 
two independent groups associated with PPP1CC2-CT peptide treatments in bovine 
spermatozoa. NC, negative control; PM, progressive motility; NPM, non-progressive 
motility; IM, immotile spermatozoa. Data are expressed as mean of three independent 
experiments performed in triplicate. 
Variable Groups (5uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
PPP1CC2-CT / NC 
Student's T-test 0,001 NC 
PM slow Student's T-test 0,026 NC 
NPM Student's T-test 0,154 - 
IM Student's T-test 0 PPP1CC2-CT 
Variable Groups (10uM) Test Sig. (2-tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
PPP1CC2-CT / NC 
Student's T-test 0,001 NC 
PM slow Student's T-test 0,423 - 
NPM Student's T-test 0,234 - 
IM Student's T-test 0,029 PPP1CC2-CT 
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Supplementary Table 8 - Inferential statistics; Test for differences between means of two 
independent groups associated with AKAP4 peptides treatments in bovine spermatozoa. 
NC, negative control; PM, progressive motility; NPM, non-progressive motility; IM, 
immotile spermatozoa. Data are expressed as mean of three independent experiments 
performed in triplicate. 
Variable Groups (5uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast  
AKAP4 BM / NC 
Student's T-test 0 NC 
PM slow Student's T-test 0,114 - 
NPM Student's T-test 0,171 - 
IM Student's T-test 0 AKAP4-BM 
Variable Groups (10uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
AKAP4 BM / NC 
Student's T-test 0 NC 
PM slow Student's T-test 0,042 NC 
NPM Student's T-test 0,69 - 
IM Student's T-test 0 AKAP4-BM 
Variable Groups (5uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
AKAP4 BM M / NC 
Student's T-test 0,039 NC 
PM slow Student's T-test 0,564 - 
NPM Student's T-test 0,308 - 
IM Student's T-test 0,204 - 
Variable Groups (10uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
AKAP4 BM M / NC 
Student's T-test 0,981 - 
PM slow Student's T-test 0,862 - 
NPM Student's T-test 0,283 - 
IM Student's T-test 0,773 - 
Variable Groups (5uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
AKAP4 BM / 
AKAP4 BM M 
Student's T-test 0,001 AKAP4-BM M 
PM slow Student's T-test 0,271 - 
NPM Student's T-test 0,657 - 
IM Student's T-test 0,028 AKAP4-BM 
Variable Groups (10uM) Test Sig. (2 tailed) 
Interpretation Unilateral Test 
% of spermatozoa (variable) is 
significantly higher in 
PM fast 
AKAP4 BM / 
AKAP4 BM M 
Student's T-test 0,003 AKAP4-BM M 
PM slow Student's T-test 0,025 AKAP4-BM M 
NPM Student's T-test 0,289 - 
IM Student's T-test 0,004 AKAP4-BM 
 60 
Supplementary Table 9 - PPP1CC2-CT peptide’s putative interactors identified by LC-MS/MS analysis. 
 
Uniprot 
ID Protein name Gene name Peptides 
Razor + 
unique 
peptides 
Unique 
peptides 
Sequence 
coverage 
[%] 
Unique + 
razor 
sequence 
coverage [%] 
Unique 
sequence 
coverage [%] 
Score 
Q00577 Transcriptional activator protein Pur-alpha PURA 10 10 10 39,8 39,8 39,8 323,31 
P02788 Lactotransferrin LTF 20 20 20 30,7 30,7 30,7 323,31 
Q9Y2T7 Y-box-binding protein 2 YBX2 5 2 2 19 9,1 9,1 171,2 
Q75WM6 Testis-specific H1 histone H1FNT 3 3 3 12,2 12,2 12,2 24,443 
P11940 Polyadenylate-binding protein 1 PABPC1 17 17 12 26,6 26,6 18,2 323,31 
P43155 Carnitine O-acetyltransferase CRAT 14 14 14 25,4 25,4 25,4 109,49 
P37108 Signal recognition particle 14 kDa protein SRP14 5 5 5 33,1 33,1 33,1 84,675 
Q6NUI6 Chondroadherin-like protein CHADL 6 6 6 12,6 12,6 12,6 31,79 
O75569 Interferon-inducible double-stranded RNA-dependent protein kinase activator A PRKRA 6 6 6 24,9 24,9 24,9 51,187 
P48729 
Q8N752 
Casein kinase I isoform alpha 
Casein kinase I isoform alpha-like 
CSNK1A1 
CSNK1A1L 6 6 6 19,3 19,3 19,3 12,46 
Q7L2E3 Putative ATP-dependent RNA helicase DHX30 DHX30 14 14 14 16,2 16,2 16,2 42,423 
Q9Y4P3 Transducin beta-like protein 2 TBL2 6 6 6 17,2 17,2 17,2 30,489 
P04279 Semenogelin-1 SEMG1 15 15 12 39,4 39,4 32 203,77 
Q8N0Z8 tRNA pseudouridine synthase-like 1 PUSL1 6 6 6 26,1 26,1 26,1 21,378 
A4D1T9 Probable inactive serine protease 37 PRSS37 4 4 4 18,3 18,3 18,3 41,194 
Q96A08 Histone H2B type 1-A HIST1H2BA 6 3 3 40,9 19,7 19,7 248,39 
Q9BTE6 Alanyl-tRNA editing protein Aarsd1 AARSD1 7 7 7 26,2 26,2 26,2 48,729 
Q9Y2C4 Nuclease EXOG, mitochondrial EXOG 4 4 4 16,3 16,3 16,3 9,8266 
O95782 
O94973 
AP-2 complex subunit alpha-1 
AP-2 complex subunit alpha-2 
AP2A1 
AP2A2 4 4 4 5 5 5 6,8889 
Q07021 Complement component 1 Q subcomponent-binding protein, mitochondrial C1QBP 3 3 3 15,6 15,6 15,6 6,2494 
Q6X784 Zona pellucida-binding protein 2 ZPBP2 4 4 4 13,6 13,6 13,6 15,524 
Q14997 Proteasome activator complex subunit 4 PSME4 12 12 12 9,2 9,2 9,2 43,811 
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Uniprot 
ID Protein name Gene name Peptides 
Razor + 
unique 
peptides 
Unique 
peptides 
Sequence 
coverage 
[%] 
Unique + 
razor 
sequence 
coverage [%] 
Unique 
sequence 
coverage [%] 
Score 
P61626 Lysozyme C LYZ 2 2 2 14,2 14,2 14,2 11,965 
Q9UHI8 A disintegrin and metalloproteinase with thrombospondin motifs 1 ADAMTS1 2 2 2 3 3 3 3,3085 
Q9H0B8 Cysteine-rich secretory protein LCCL domain-containing 2 CRISPLD2 5 5 5 13,3 13,3 13,3 13,505 
Q02383 Semenogelin-2 SEMG2 9 6 6 22,7 16,8 16,8 25,709 
P10323 Acrosin ACR 8 8 8 17,1 17,1 17,1 119,51 
Q8TDZ2 Protein-methionine sulfoxide oxidase MICAL1 MICAL1 6 6 6 8,4 8,4 8,4 12,087 
Q92820 Gamma-glutamyl hydrolase GGH 7 7 7 25,2 25,2 25,2 21,552 
P61163 Alpha-centractin ACTR1A 10 10 8 35,6 35,6 31,1 156,13 
P05154 Plasma serine protease inhibitor SERPINA5 3 3 3 9,6 9,6 9,6 4,5206 
Q8IVS2 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial MCAT 3 3 3 13,8 13,8 13,8 10,428 
Q13618 Cullin-3 CUL3 19 19 19 29,6 29,6 29,6 192,32 
P36969 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial GPX4 2 2 2 13,2 13,2 13,2 7,9002 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial DECR1 13 13 13 50,1 50,1 50,1 323,31 
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial ECH1 2 2 2 7,3 7,3 7,3 4,224 
P10909 Clusterin CLU 8 8 8 22,3 22,3 22,3 142,13 
O75390 Citrate synthase, mitochondrial CS 10 10 10 29,2 29,2 29,2 67,451 
P36957 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial DLST 2 2 2 4,6 4,6 4,6 5,4474 
P67809 
P16989 
Nuclease-sensitive element-binding protein 1 
Y-box-binding protein 3 
YBX1 
YBX3 6 6 3 26,5 26,5 15,4 323,31 
P36873 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit PPP1CC 4 4 4 11,1 11,1 11,1 26,987 
Q9Y285 Phenylalanine--tRNA ligase alpha subunit FARSA 4 4 4 9,8 9,8 9,8 19,284 
Q9UGP8 Translocation protein SEC63 homolog SEC63 2 2 2 2,6 2,6 2,6 2,5174 
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 7 7 7 17 17 17 32,19 
Q6JEL2 Kelch-like protein 10 KLHL10 3 3 3 5,9 5,9 5,9 3,9091 
Q92523 Carnitine O-palmitoyltransferase 1, muscle isoform CPT1B 7 7 7 10,6 10,6 10,6 18,443 
Q04837 Single-stranded DNA-binding protein, mitochondrial SSBP1 4 4 4 33,8 33,8 33,8 43,69 
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Supplementary Figure 1 – Ponceau S. staining used as loading control in blot overlay.  
 
 
Supplementary Figure 2 – Immunoblot with mouse anti-β-tubulin antibody used as 
loading control in blot overlay.  
 
